Page last updated: 2024-09-03

imatinib mesylate and Acute Lymphoid Leukemia

imatinib mesylate has been researched along with Acute Lymphoid Leukemia in 414 studies

Research

Studies (414)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.24)	18.2507
2000's	198 (47.83)	29.6817
2010's	171 (41.30)	24.3611
2020's	44 (10.63)	2.80

Authors

Authors	Studies
Atsuta, Y; Cho, R; Dobashi, N; Doki, N; Fujisawa, S; Fujita, H; Hagihara, M; Hata, T; Hatta, Y; Hayakawa, F; Hiramoto, N; Hirano, D; Ishikawa, Y; Ito, T; Kako, S; Kamae, T; Kobayashi, Y; Matsuda, M; Miyazaki, Y; Naoe, T; Nishiwaki, S; Ohtake, S; Onoda, M; Ozawa, Y; Sakura, T; Suehiro, Y; Sugiura, I; Tanaka, M; Taniguchi, Y; Tsuji, M; Ueda, Y; Yokoyama, H	1
Baek, DW; Choi, Y; Jung, SH; Kim, DY; Koh, Y; Moon, JH; Sohn, SK; Yhim, HY	1
Buono, R; Duong, MR; Fruman, DA; Gotesman, M; Herzog, LO; Lee, JS; Mallya, S; Thao, J; Vo, TT	1
Adachi, S; Hirai, H; Hirata, M; Imai, Y; Kamikubo, Y; Kataoka, TR; Kato, I; Kimura, S; Koyama, A; Kubota, H; Maeda, S; Masuda, T; Matsuo, H; Mitsuda, Y; Mizuta, S; Morita, K; Naka, K; Nakahata, T; Sakuramoto, N; Shimada, S; Sugiyama, H; Suzuki, K; Takita, J; Tanaka, K	1
Ashraf, S; Bachiashvili, K; Bhatia, R; Jamy, O; Rangaraju, S; Vachhani, P; Wolfson, J	1
Akisada, N; Ishihara, T; Nogami, K; Ochi, S; Watakabe, M	1
Beck, JC; Patel, SA	1
Andrade, A; Bass, F; Benavente, R; Cabrera, ME; Cid, F; Encina, A; Molina, J; Monardes, V; Puga, B	1
Badell Serra, I; de la Fuente Regaño, L; Díaz de Heredia Rubio, C; Galán Gómez, V; González Vicent, M; Isabel Pascual Martínez, A; López Duarte, M; María Fernández, J; María Pérez Hurtado, J; Pérez-Martínez, A; Rodríguez Villa, A; Soledad Maldonado Regalado, M	1
Akahane, K; Goi, K; Harama, D; Inukai, T; Kagami, K; Kasai, S; Nguyen, TTT; Tamai, M; Watanabe, A	1
Heitmann, JS; Hinterleitner, C; Hörner, S; Jung, G; Kauer, J; Märklin, M; Pflügler, M; Salih, HR; Tandler, C	1
Alonso, N; Bermúdez, A; Cano-Ferri, I; Esteban, D; Esteve, J; García-Calduch, O; García-Fortes, M; García-Sanz, R; Genescà, E; González-Campos, J; Martínez, P; Martínez-Lopez, J; Mercadal, S; Montesinos, P; Ribera, J; Ribera, JM; Torrent, A	1
Haddad, FG; Jabbour, E; Kantarjian, H; Short, NJ	1
Dirse, V; Norvilas, R; Stankeviciene, S; Stukaite-Ruibiene, E; Vaitkeviciene, GE	1
Appelmann, I; Brümmendorf, TH; Koschmieder, S; Maletzke, S; Masouleh, BK; Salimi, A; Schemionek, M; Schroeder, KM; Vieri, M	1
Haddad, FG; Short, NJ	1
Al-Qattan, Y; Ali, S; AlShemmari, S; Awny, W; Hamadah, A; Pinto, K	1
Chen, C; Li, X; Qi, J; Yongjing, W	1
Bai, L; Chen, J; Chen, Y; Cui, J; Gu, X; Han, W; Hu, Z; Li, H; Li, W; Niu, C; Yang, Y; Zhang, X; Zhou, L	1
Mori, N; Motoji, T; Okada, M; Sameshima, Y; Shiseki, M; Tanaka, J	1
Chen, YQ; Hua, XL; Le, SH; Li, J; Zheng, YZ	1
Dobi, B; Freitag, A; Patos, P; Prawitz, T; Ribera, JM; Rizzo, F; Sabatelli, L; Sharma, A	1
Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L	1
Biondi, A; Borowitz, MJ; Cario, G; Carroll, AJ; Cazzaniga, G; Devidas, M; Gastier-Foster, JM; Heerema, NA; Hunger, SP; Loh, ML; Martin-Regueira, P; Moorman, AV; Raetz, EA; Reshmi, SC; Saha, V; Schrappe, M; Schultz, KR; Silverman, LB; Slayton, WB; Tran, TH; Valsecchi, MG	1
Akahoshi, Y; Atsuta, Y; Fukuda, T; Ichinohe, T; Kako, S; Kanda, Y; Mizuta, S; Nakamae, H; Nishiwaki, S; Ohashi, K; Onizuka, M; Ozawa, Y; Shiratori, S; Takahashi, S; Tanaka, M; Uchida, N	1
Barberi, W; Cazzaniga, G; Chiaretti, S; De Propris, MS; Del Giudice, I; Della Starza, I; Fazio, F; Fazio, G; Foà, R; Guarini, A; Mancini, F; Messina, M; Mohamed, S; Moleti, ML; Testi, AM	1
Lei, Q; Teng, Z; Xu, S	1
Rabin, KR	1
Cai, J; Chen, X; Cheng, C; Fang, Y; Gao, J; Hu, Q; Hu, S; Jeha, S; Jiang, H; Jin, R; Ju, X; Li, C; Li, CK; Liang, C; Pan, K; Pei, D; Pui, CH; Shen, S; Sun, L; Tang, J; Tian, X; Wang, N; Wu, X; Yang, JJ; Yang, M; Yu, J; Zhai, X; Zhang, H; Zhu, X; Zhu, Y	1
Stirrups, R	1
Killock, D	1
Jin, J; Li, XY; Meng, HT; Qian, JJ; Tong, HY; Wang, SS; Yang, M; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH	1
Bonifacio, M; Candoni, A; Chiaretti, S; Ciccone, M; Curti, A; Fava, C; Ferrara, F; Foà, R; Pizzolo, G	1
Burke, MJ; Egelund, TA; Katzenstein, HM; Liberio, N; Ng, JS; Pommert, L; Siver, MJ	1
Jia, YP; Lu, AD; Wu, J; Zhang, LP; Zheng, FY; Zuo, YX	1
Hatta, Y; Hayakawa, F; Yamazaki, E	1
Byrd, K; Chang, BH; Druker, BJ; Hayes-Lattin, B; Kosaka, Y; Lamble, A; LaTocha, D; Leonard, JT; Lind, E; Malla, P; Tyner, JW	1
Feng, J; Gao, S; Liang, B; Shi, Y; Wu, D; Xing, C; Xu, W; Zhou, B; Zhou, Y	1
Aoyama, T; Fuseya, H; Hayashi, Y; Horiuchi, M; Nakao, T; Nakaya, Y; Sakagami, R; Tatsumi, N; Tsutsumi, M; Yamane, T; Yamasaki, K; Yoshida, M; Yoshimura, T	1
Dobashi, N	1
Deng, L; Fan, Z; Huang, F; Jin, H; Li, X; Liang, X; Lin, D; Lin, R; Liu, H; Liu, Q; Ma, L; Nie, D; Sun, J; Xu, D; Xu, N; Xuan, L; Ye, J; Zhang, Y	1
Chen, M; Lin, Y; Tengwang, T; Zhang, L; Zhu, Y	1
Cheon, JE; Choi, JY; Choi, S; Hong, KT; Kang, HJ; Kim, BK; Shin, HY; Yul Ahn, H	1
Adachi, S; Hiramatsu, H; Kamitori, T; Kato, I; Mikami, T; Ogata, H; Oiki, N; Okamoto, S; Okamoto, T; Takita, J; Tanaka, K; Tasaka, K; Umeda, K	1
Cao, W; Jiang, Z; Li, L; Li, X; Li, Y; Wan, D; Yu, J; Zhang, S	1
Jin, J; Li, C; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Xu, W; Yu, W	1
Chen, H; Chen, YH; Huang, XJ; Lai, YY; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH	1
Gong, YP; Guo, Y; Huang, XO; Li, Y; Ma, HB; Wang, FF; Xiang, B	1
Jabbour, E; Kantarjian, H; Ravandi, F; Short, NJ	1
Maese, L; Raetz, EA; Tasian, SK	1
Alten, J; Aricò, M; Biondi, A; Bleckmann, K; Castor, A; Cavé, H; Cazzaniga, G; Conter, V; De Lorenzo, P; Escherich, G; Ferrari, GM; Gandemer, V; Hancock, J; Köhler, R; Leoni, V; Madsen, HO; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stadt, UZ; Stary, J; Valsecchi, MG; van der Velden, V; Zuna, J	1
Fujimaki, K; Hattori, Y; Nakajima, H	1
Chen, H; Huang, XJ; Jia, JS; Jiang, B; Jiang, H; Jiang, Q; Liu, KY; Qin, YZ; Ruan, GR; Wang, J; Xu, LP; Zhang, XH; Zhao, T	1
Gaynon, PS	1
Cortelezzi, A; Fracchiolla, NS; Sciumè, M	1
Cao, WB; Chen, SL; Feng, SZ; Gong, M; Han, MZ; He, Y; Jiang, EL; Sun, JL; Yang, DL; Yao, JF; Zhang, RL; Zheng, XH; Zhou, LK	1
Dobashi, N; Doki, N; Hatta, Y; Hayakawa, F; Ito, Y; Iwanaga, M; Kanamori, H; Kiyoi, H; Maeda, T; Matsuo, K; Miyazaki, Y; Mizuta, S; Monma, F; Naoe, T; Ohtake, S; Sugiura, I; Takeuchi, J; Ueda, Y; Yoshida, C; Yujiri, T	1
Feng, J; Jiang, S; Liang, B; Qian, Y; Shen, Z; Tang, L; Wu, J; Xing, C; Yu, K; Zhuang, Q	1
Attarbaschi, A; Biondi, A; Bradtke, J; Campbell, M; Cario, G; Castor, A; Conter, V; De Lorenzo, P; Escherich, G; Gandemer, V; Leoni, V; Li, CK; Pieters, R; Saha, V; Schrappe, M; Stary, J; Valsecchi, MG; Vora, A	1
Baruchel, A; Biondi, A; Bradtke, J; Campbell, M; Cario, G; Castor, A; Cavé, H; Cazzaniga, G; Conter, V; De Lorenzo, P; Escherich, G; Gandemer, V; Grazia Valsecchi, M; Leoni, V; Li, CK; Pieters, R; Saha, V; Schrappe, M; Stary, J; Vora, A	1
Chen, H; Chen, YH; Cheng, YF; Han, W; Huang, XJ; Jia, YP; Liu, KY; Lu, AD; Sun, YQ; Suo, P; Wang, Y; Wu, J; Xu, LP; Xue, YJ; Yan, CH; Zhang, LP; Zuo, YX	1
Barel, O; Bielorai, B; Cal, N; Fisher, T; Golan, H; Goldstein, G; Leitner, M; Marcu, V; Mehrian-Shai, R; Schiby, G; Toren, A; Trakhtenbrot, L; Yalon, M	1
Abella, E; Amigo, ML; Artola, MT; Barba, P; Barrios, M; Bravo, P; Cervera, M; Feliu, E; García, O; García-Belmonte, D; García-Cadenas, I; García-Guiñón, A; Genescà, E; Gil, C; González-Campos, J; Hernández-Rivas, JM; Lavilla, E; Martínez-Carballeira, D; Mercadal, S; Montesinos, P; Moreno, MJ; Novo, A; Ribera, J; Ribera, JM; Serrano, J; Tormo, M; Vives, S	1
Gupta, B; Kumar, A; Pant, G; Pooniya, V; Sharma, A; Verma, N	1
Han, J; Hao, J; Jin, R; Qiu, Y; Qu, P; Yu, H; Zhou, F	1
Decorti, G; Franca, R; Londero, M; Rabusin, M; Stocco, G; Verzegnassi, F	1
Inoue, M; Kawa, K; Kondo, O; Sato, M; Sawada, A; Yamada, K; Yasui, M	1
Cen, JN; Chen, Y; Chen, ZX; Ding, ZX; He, J; Pan, JL; Qiu, QC; Shen, HJ; Yao, L	1
Chen, F; Chen, J; Qiu, HY; Sun, AN; Wu, DP; Zhao, Y	1
Badell, I; Camós, M; Estella, J; Fernández-Delgado, R; Fernández-Teijeiro, A; Gómez, P; Lendínez, F; López-Almaraz, R; Melo, M; Moreno, MJ; Rives, S; Uriz, JJ; Verdeguer, A; Vivanco, JL	1
Despas, F; Laurent, G; Roche, H	1
Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM	1
Mandavilli, A	1
Ge, Z; Hong, M; Li, JY; Pan, LQ; Qian, SX; Song, P; Tian, T; Yu, H; Zhang, SJ; Zhu, Y	1
Doki, N; Kakihana, K; Kobayashi, T; Ohashi, K; Oshikawa, G; Sakamaki, H	1
Cao, J; Chen, C; Li, ZY; Lü, C; Song, XG; Xu, KL; Yan, ZL; Zeng, LY; Zhang, HX	1
Bowyer, S; Fedoriw, G; Hayden, MA; Hsu, J; Mullighan, CG; Rao, KW; Roberts, KG; Weston, BW	1
Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S	1
Akita, N; Hattori, H; Horibe, K; Maeda, N; Sekimizu, M; Ueki, H; Yamashita, Y	1
Chopra, YR; Ramzan, M; Verma, R; Yadav, SP	1
Gong, Y; He, G; Shi, F; Shi, R; Yang, X; Zheng, B	1
Barozzi, P; Basso, S; Comoli, P; Fantuzzi, V; Forghieri, F; Iacobucci, I; Lagreca, I; Luppi, M; Maccaferri, M; Maffei, R; Marasca, R; Martinelli, G; Messerotti, A; Morselli, M; Narni, F; Paolini, A; Potenza, L; Quadrelli, C; Riva, G; Vallerini, D; Zanetti, E	1
Buck, G; Fielding, AK; Foroni, L; Gerrard, G; Goldstone, AH; Lazarus, H; Litzow, MR; Luger, SM; Marks, DI; McMillan, AK; Moorman, AV; Paietta, E; Patel, B; Rowe, JM; Tallman, MS	1
Biondi, A; Cavé, H; Cazzaniga, G; De Lorenzo, P; den Boer, ML; Harrison, CJ; Mottadelli, F; Pieters, R; Saha, V; Schrappe, M; Stanulla, M; Te Kronnie, G; Trka, J; Valsecchi, MG; van der Veer, A; Zaliova, M	1
Baccarani, M; Bonifacio, M; Bresciani, P; Cavo, M; De Benedittis, C; Gozzini, A; Iacobucci, I; Intermesoli, T; Luppi, M; Martinelli, G; Orlandi, E; Pane, F; Paolini, S; Papayannidis, C; Rigolin, GM; Russo, D; Salvucci, M; Sica, S; Soverini, S; Venturi, C	1
Aledo, A; Borowitz, MJ; Bowman, WP; Camitta, B; Carroll, A; Carroll, WL; Davies, SM; Devidas, M; Gaynon, PS; Heerema, NA; Hunger, SP; Jorstad, D; Rutledge, R; Sather, H; Schultz, KR; Slayton, WB; Trigg, M; Winick, N; Zheng, HW	1
Guillet, S; Hirsch, P; Legrand, O; Marie, JP; Marzac, C; Mohty, M	1
Bhojwani, D; Campana, D; Cheng, C; Choi, JK; Coustan-Smith, E; Howard, SC; Inaba, H; Jacobsen, J; Jeha, S; Metzger, ML; Pei, D; Pui, CH; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Shurtleff, SA	1
Bassan, R	2
Hatta, Y	1
Chen, J; Du, S; Hu, J; Li, J; Shen, Z; Wang, A; Wu, W; You, J; Zhou, L	1
Bao, L; Chen, H; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Qin, Y; Wang, J; Yang, S	1
Chen, F; Chen, G; Cheng, Z; Fu, C; Jin, Z; Qiu, H; Sun, A; Tang, X; Wu, D; Xue, S; Zhao, L	1
Bassan, R; Imbergamo, S; Maino, E; Sancetta, R; Scattolin, AM; Vespignani, M; Viero, P	1
McElligott, F; O'Marcaigh, A; O'Rafferty, C; Smith, O; Storey, L	1
Feng, S; Han, M; Huang, Y; Jiang, E; Liu, X; Ma, Q; Pang, A; Qiu, L; Wei, J; Yang, D; Zhang, R	1
Cerny-Reiterer, S; Gleixner, KV; Hadzijusufovic, E; Herrmann, H; Jäger, U; Maeda, H; Melo, JV; Meyer, RA; Peter, B; Pickl, WF; Sperr, WR; Stefanzl, G; Valent, P	1
Handa, H; Hatsumi, N; Nojima, Y; Sakura, T; Shimizu, H; Takada, S; Yokohama, A	1
Arthur, C; Boyd, AW; Bradstock, K; D'Rozario, J; Durrant, S; Ellacott, J; Filshie, R; Grigg, A; Hughes, TP; Irving, I; Lickliter, JD; Lynch, K; Rooney, K; Seldon, M; Szer, J; Taylor, K	1
Ahlberg, L; Åström, M; Hägglund, H; Hallböök, H; Hulegårdh, E; Karbach, H; Karlsson, K; Markuszewska, A; Persson, I	1
Barba, P; Bernal, T; Bethencourt, C; Brunet, S; Cervera, J; Del Potro, E; Feliu, E; Fernández-Abellán, P; González-Campos, J; Granada, I; Grande, C; Grau, J; Hernández-Rivas, JM; Montesinos, P; Moreno, MJ; Morgades, M; Motlló, C; Ribera, JM; Sarrà, J; Tormo, M	1
Sugiura, I	1
Koh, K	1
Jin, XB; Li, L; Lin, XH; Liu, MY; Mao, JW; Pu, QH; Wang, WZ; Wu, LR; Wu, QQ; Zhu, JY	1
Grant, S; Hawkins, E; Kmieciak, M; Kolluri, A; Lin, H; Nguyen, T; Park, H	1
Cho, BS; Cho, SG; Eom, KS; Han, K; Jeon, YW; Kim, DW; Kim, HJ; Kim, M; Kim, Y; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, J; Shin, SH; Yahng, SA; Yoon, JH	1
Lin, L; Lu, XJ; Song, XB; Wang, J; Ye, YX; Ying, BW; Zhou, J; Zhou, Y; Zhou, YH	1
Chen, XY; Chen, YJ; Zheng, YL	1
Cho, JH; Jang, JH; Kim, HJ; Kim, SH; Lee, ST; Shin, SY	1
Atkins, KL; Baer, MR; Duffy, AP; Kimball, AS; Mainor, CB	1
Horibe, K; Kato, I; Kato, K; Kato, M; Kawasaki, H; Kodama, Y; Kudo, K; Manabe, A; Matsumoto, K; Saito, AM; Saito, T; Sato, A; Shimada, H; Tsurusawa, M; Yabe, H	1
Borthakur, G; Cortes, J; Daver, N; Garcia-Manero, G; Garris, R; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Ravandi, F; Rytting, M; Thomas, D	1
Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH	1
Biondi, A; Leoni, V	1
Boer, JM; Cornelissen, JJ; den Boer, ML; Exalto, C; Koenders, JE; Rijneveld, AW; Sanders, MA; Valk, PJ; van der Holt, B	1
Abbal, C; Berthon, C; Cayuela, JM; Chalandon, Y; Chevret, S; Dombret, H; Escoffre-Barbe, M; Hayette, S; Huguet, F; Ifrah, N; Lafage-Pochitaloff, M; Lambert, JF; Leguay, T; Lepretre, S; Lhéritier, V; Maury, S; Raffoux, E; Rousselot, P; Tavernier, E; Thomas, X	1
Fukushima, H; Fukushima, T; Kobayashi, C; Nanmoku, T; Sakai, A; Satomi, K; Sumazaki, R; Suzuki, R; Tagawa, M	1
Bardy-Bouxin, N; Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Matczak, E; Shapiro, M; Turkina, AG; Turnbull, K	1
Chen, C; Chen, W; Li, D; Li, Z; Qiu, T; Song, X; Xu, K; Yan, Z; Zeng, L; Zhang, H; Zhang, P	1
Gong, Y; Lin, J; Liu, X; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X	1
Bae, SH; Chi, HS; Eom, HS; Hyun, MS; Jang, DY; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, HJ; Kim, I; Kim, MK; Lee, GW; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, S; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yun, SC	1
Chen, XJ; Guo, Y; Liu, F; Liu, TF; Liu, XM; Qi, BQ; Ruan, M; Wang, SC; Yang, WY; Zhang, JY; Zhang, L; Zhu, XF; Zou, Y	1
Gong, Y; Len, Y; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X	1
Bao, L; Chen, H; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Liu, K; Lu, J; Wang, J; Xu, L; Yang, S; Zhang, X; Zhao, T; Zhu, H	1
Feng, S; Liu, Q; Yang, D	1
Akashi, K; Eto, T; Henzan, H; Ito, Y; Kamimura, T; Kato, K; Miyamoto, T; Nagafuji, K; Ohno, Y; Takase, K; Takashima, S; Techima, T; Yoshida, S; Yoshimoto, G	1
Feng, S; Han, M; He, Y; Liu, Q; Shi, Y; Yang, D; Zhang, R	1
Akao, Y; Ito, Y; Kumazaki, M; Kuranaga, Y; Minami, Y; Naoe, T; Otsuki, Y; Shinohara, H; Sugito, N; Taniguchi, K; Yamada, N	1
Gao, XN; Guo, YL; Han, XP; Jin, XS; Jing, Y; Liu, K; Yao, ZL; Yu, L; Zhang, R	1
Bleckmann, K; Schrappe, M	1
Gong, Y; Naren, D; Shi, F; Shi, R; Wang, K; Wu, J; Xu, W; Yan, T; Yang, X	1
Chang, H; Cui, X; Dai, Y; Dong, T; He, C; Huang, J; Ji, J; Kuang, P; Li, J; Liang, X; Liu, T; Lu, X; Ma, H; Niu, T; Pan, L; Qing, S; Wang, X; Wu, C; Wu, H; Wu, Y; Xiang, B; Ye, Y; Zhu, H	1
Albano, F; Baccarani, M; Castagnetti, F; Cavo, M; Crugnola, M; De Benedittis, C; Gugliotta, G; Iurlo, A; Klamova, H; Linhartova, J; Mancini, M; Martinelli, G; Papayannidis, C; Polakova, KM; Rosti, G; Russo, D; Salvucci, M; Soverini, S	1
Cai, W; Chen, S; He, J; Liu, B; Shen, H; Sun, A; Wu, D; Xu, Y	1
Cao, R; Fan, ZP; Huang, F; Huang, JX; Li, H; Li, L; Li, X; Li, YL; Liu, QF; Liu, XL; Liu, Z; Lu, ZY; Xu, N; Zhang, S; Zhou, HS; Zhou, X; Zhu, HQ	1
Califano, C; Chiaretti, S; De Fabritiis, P; Dore, F; Elia, L; Falini, B; Fanin, R; Fazi, P; Ferrara, F; Foà, R; La Nasa, G; Luppi, M; Mandelli, F; Meloni, G; Piciocchi, A; Ronco, F; Tedeschi, A; Vignetti, M; Vitale, A	1
Heiblig, M; Thomas, X	1
Eskazan, AE	1
Huang, QR; Jia, YQ; Jiang, NG; Jin, YM; Li, HF; Li, X; Meng, WT; Mo, XM; Xu, H; Zeng, TT	1
Andrews, LM; Atiq, F; Broers, AE; Doorduijn, JK; Koch, BC; Van Gelder, T; Versmissen, J	1
Capitani, S; Martelli, AM; McCubrey, JA; Milani, D; Neri, LM; Simioni, C; Ultimo, S; Zauli, G	1
Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P	1
Litzow, MR	1
Asnafi, V; Bastié, JN; Bay, JO; Beldjord, K; Béné, MC; Bernard, M; Charbonnier, A; Chevallier, P; Desjonquères, A; Dombret, H; Himberlin, C; Huguet, F; Hunault, M; Ifrah, N; Isnard, F; Lafage-Pochitaloff, M; Leguay, T; Lepretre, S; Lhéritier, V; Lioure, B; Renaud, M; Tavernier, E; Thomas, X; Turlure, P	1
Benton, CB; Cameron Yin, C; Cortes, JE; Daver, NG; Garcia-Manero, G; Garris, R; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Khouri, M; Ko, H; Konopleva, M; O'Brien, SM; Patel, K; Ravandi, F; Sasaki, K; Short, NJ; Thomas, D	1
Adachi, S; Hiramatsu, H; Horibe, K; Ishii, E; Kaneko, T; Kato, I; Kato, K; Kato, M; Kawasaki, H; Kodama, Y; Manabe, A; Matsumoto, K; Mizutani, S; Oda, M; Saito, AM; Sano, H; Sato, A; Shimada, H	1
Akiyama, H; Aoyama, Y; Dobashi, N; Fujisawa, S; Hatta, Y; Imai, K; Kakihana, K; Maeda, T; Matsuo, K; Miyazaki, Y; Mizuta, S; Naoe, T; Ohnishi, K; Ohtake, S; Onishi, Y; Sugiura, I; Ueda, Y	1
Alvarnas, JC; Blume, KG; Cherry, AM; Forman, SJ; Laport, GG; Negrin, RS; Palmer, JM; Slovak, ML; Snyder, DS; Wong, RM	1
Breeden, M; Cortes, JE; Giles, FJ; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Thomas, D; Yin, CC; Zhao, W	1
Amabile, M; Arruga, F; Baccarani, M; Baruzzi, A; Berton, G; Chiaretti, S; Cilloni, D; Foà, R; Giannoulia, P; Iacobucci, I; Lonetti, A; Martinelli, G; Messa, F; Ottaviani, E; Pane, F; Paolini, S; Papayannidis, C; Perini, G; Piccaluga, PP; Poerio, A; Saglio, G; Soverini, S; Vitale, A	1
Baeumler, J; Falkenburg, JH; Nijmeijer, BA; Ottmann, OG; Szuhai, K; van Schie, ML	1
Seth, R; Thavaraj, V	1
Arima, N; Fujiwara, H; Hamada, H; Matsushita, K; Ozaki, A; Tei, C; Yoshimitsu, M	1
Ohno, R	2
Abou Mourad, YR; Fernandez, HF; Kharfan-Dabaja, MA	1
Duyster, J; Götze, KS; Kancha, RK; Miething, C; Peschel, C; von Bubnoff, N	1
Baker, KS; Burke, MJ; Luo, X; Trotz, B; Verneris, MR; Wagner, JE; Weisdorf, DJ	1
Hirase, C; Kanamaru, A; Maeda, Y; Takai, S	1
Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F	1
Usui, N	3
Aoki, T; Kimura, S; Matsue, K; Odawara, J; Takeuchi, M; Yamakura, M	1
Cortes, J; Quintás-Cardama, A	1
Apostolidis, J; Charitaki, E; Harhalakis, N; Liapis, K; Nikiforakis, E; Panitsas, F	1
Chen, H; Chen, Y; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Lu, DP; Wang, J; Wang, Y; Xu, LP; Zhang, XH; Zhang, YC	1
Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R	1
Cimino, G; Elia, L; Foà, R; Grammatico, S; Matarazzo, M; Pane, F; Pedace, L; Peluso, AL; Rago, A; Vitale, A	1
Chung, NG; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Lim, J; Min, CK; Min, WS	1
Auclerc, MF; Baruchel, A; Cayuela, JM; Chevret, S; Debre, M; Demeocq, F; Gandemer, V; Jonveaux, P; Le Gall, E; Lejars, O; Leverger, G; Perel, Y; Piguet, C; Schmitt, C; Stephan, JL; Vannier, JP	1
Alessandrino, EP; Bernasconi, P; Boni, M; Bonvini, L; Calatroni, S; Colombo, AA; Merante, S; Rocca, B; Soverini, S	1
Gastl, G; Haun, M; Hoflehner, E; Kircher, B; Nachbaur, D; Petzer, A; Schumacher, P; Wolf, AM	1
Buck, G; Dewald, G; Durrant, IJ; Fielding, AK; Foroni, L; Franklin, IM; Goldstone, AH; Lazarus, HM; Litzow, MR; Luger, SM; Marks, DI; McMillan, AK; Moorman, AV; Paietta, E; Richards, SM; Rowe, JM; Tallman, MS; Wiernik, PH	1
Li, Y; Mi, Y; Qiu, L; Wang, J; Zhao, Y; Zou, D	2
Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S	1
Du, QF; Liu, QF; Liu, XL; Liu, Z; Meng, FY; Song, LL; Xu, N; Yi, ZS; Zhong, M; Zhou, SY	1
Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N	1
Gruber, F; Mustjoki, S; Porkka, K	1
Isidori, A; Malagola, M; Piccaluga, P; Visani, G	1
Amagasaki, T; Branford, S; Hughes, T; Ishikawa, J; Jinnai, I; Kawaguchi, T; Kobayashi, Y; Maeda, Y; Miyamura, K; Miyazaki, Y; Naoe, T; Natori, H; Nishimura, M; Ohyashiki, K; Okada, M; Okamoto, S; Tanaka, H; Tanii, H; Tojo, A; Urabe, A; Usui, N; Usuki, K	1
Abruzzese, E; Apperley, JF; Bullorsky, EO; Cortes, JE; de Souza, CA; Erben, P; Heim, D; Hochhaus, A; Hughes, TP; Khoury, HJ; Kim, DW; Kim, HJ; Larson, RA; Lipton, JH; Roboz, GJ; Rosti, G; Roy, L; Sillaber, C; Stone, RM; Van Tornout, J	1
Fujiwara, H; Hayama, BY; Iwama, K; Kimura, S; Matsue, K; Matsuo, K; Takeuch, M; Yamakura, M	1
Costa, LJ	1
Ottmann, OG; Pfeifer, H	2
Garber, K	1
Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S	1
Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR	1
Burke, MJ; Desai, S; Kadota, R; Willert, J	1
Burke, MJ; Cao, Q; Kumar, A; Smith, A; Trotz, B; Verneris, MR; Weigel, B	1
Adil, SN; Kumar, S; Masood, N	1
Bernal, MT; Brunet, S; Bureo, E; de Oteyza, JP; Del Potro, E; Esteve, J; González, M; Martín-Reina, V; Moreno, MJ; Oriol, A; Parody, R; Ribera, JM; Rivas, C; Sarrá, J; Tormo, M; Vidriales, B	1
Aledo, A; Borowitz, MJ; Bowman, WP; Burden, L; Camitta, B; Carroll, A; Carroll, WL; Davies, SM; Devidas, M; Gaynon, PS; Heerema, NA; Hunger, SP; Jorstad, D; Rutledge, R; Sather, H; Schultz, KR; Slayton, WB; Trigg, M; Wang, C; Winick, N	1
Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC	1
Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP	1
Czyz, A; Komarnicki, M; Kroll, R; Lewandowski, K	1
Stock, W	1
Abe, A; Emi, N; Hayakawa, F; Imagama, S; Ito, Y; Katsumi, A; Kiyoi, H; Minami, Y; Naoe, T; Nomura, Y; Suzuki, M; Tanizaki, R; Yamamoto, K	1
Barozzi, P; Basso, S; Comoli, P; D'Amico, R; Del Giovane, C; Forghieri, F; Locatelli, F; Luppi, M; Maccaferri, M; Morselli, M; Potenza, L; Quadrelli, C; Riva, G; Torelli, G; Vallerini, D; Volzone, F; Zanetti, E	1
IMAHASHI, N; MIYAMURA, K; NISHIWAKI, S; OZAWA, Y; TOKUNAGA, M; YANAGISAWA, M	1
Enrico, A; Milone, JH	1
Ishii, S; Katayama, Y; Matsui, T; Okamura, A; Wakahashi, K; Yamamoto, K	1
Brigid Bradley-Garelik, M; Bullorsky, E; Charbonnier, A; Dombret, H; Ehninger, G; Larson, RA; Lilly, MB; Martinelli, G; Müller, MC; Ottmann, OG; Reiffers, JJ; Shah, NP; Zhu, C	1
Fullmer, A; Jabbour, E	1
Bo, J; Cai, B; Ding, Y; Gao, CJ; Gao, L; Huang, WR; Li, HH; Sun, JF; Wang, LL; Yu, L	1
Frankel, AE; Hogge, DE; Kim, HP	1
Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M	1
Skorski, T	1
Cortes, J; Kantarjian, H; O'Brien, S; Thomas, DA	1
Abe, D; Fujisawa, S; Hoshino, T; Kanamori, H; Kanda, Y; Maruta, A; Nakaseko, C; Nakasone, H; Okamoto, S; Sakura, T; Takahashi, S; Takasaki, H; Usuki, K; Yano, S; Yokota, A	1
Barr, RD	1
Chen, XC; Li, CX; Liu, H; Liu, YJ; Ma, X; Sun, DP; Wu, DP; Wu, XJ	1
Angelucci, E; Bassan, R; Borghero, C; Borlenghi, E; Cavattoni, I; Ciceri, F; Di Bona, E; Intermesoli, T; Lambertenghi-Deliliers, G; Levis, A; Mannelli, F; Mattei, D; Oldani, E; Pogliani, EM; Rambaldi, A; Romani, C; Rossi, G; Spinelli, O; Terruzzi, E; Tosi, M	1
Harigae, H; Kato, C; Kodera, Y; Miyamura, K; Nakao, S; Nishiwaki, S; Ohashi, K; Sakamaki, H; Terakura, S	1
Fielding, AK	1
Akiyama, H; Atsuta, Y; Hatta, Y; Kanamori, H; Kawa, K; Kimura, Y; Matsuo, K; Miyazaki, Y; Mizuta, S; Morishima, Y; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Sakamaki, H; Ueda, Y; Usui, N; Yagasaki, F; Yujiri, T	1
Cho, BS; Cho, SG; Jeon, EK; Kim, DW; Kim, HJ; Kim, M; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, J; Min, CK; Min, WS; Park, CW; Yahng, SA	1
Camitta, B; Prestidge, T; Schultz, KR	1
Calabrese, E; De Propris, MS; Della Starza, I; Elia, L; Foà, R; Guarini, A; Intoppa, S; Maggio, R; Milani, ML; Peragine, N; Vitale, A	1
Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ	1
Du, W; Miharu, M; Osumi, T; Shimada, H; Takahashi, T; Tanaka, R	1
Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Shi, HX; Wang, Y; Xu, LP; Zhan, XH; Zhao, T	1
Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Maruta, A; Motohashi, K; Numata, A; Sakai, R; Tachibana, T; Tanaka, M; Tomita, N	1
Lee, HJ; Thompson, JE; Wang, ES; Wetzler, M	1
Chauncey, TR; Flowers, ME; Georges, GE; Lange, T; Langston, AA; Laport, GG; Maloney, DG; Maris, MB; Ram, R; Sandmaier, BM; Storb, R; Storer, B; Woolfrey, A	1
Baer, MR; Gojo, I; Patel, SB; Sausville, EA; Tidwell, ML	1
Ravandi, F	1
Ando, K; Fujisawa, S; Iida, S; Ishizawa, K; Kobayashi, Y; Miyawaki, S; Motoji, T; Nagai, T; Ohno, R; Okada, M; Sakamaki, H; Seriu, T; Taniwaki, M; Uoshima, N; Usui, N; Yamamoto, K	1
Cortes, J; Kantarjian, H; Mathisen, MS; O'Brien, S; Ravandi, F; Thomas, D	1
Abdool, A; Bruey, JM; Yeh, CH	1
Badell, I; Couselo, JM; de Miguel, PG; Estella, J; Fernández-Delgado, R; Fernández-Teijeiro, A; Gómez, P; Lendínez, F; López-Almaraz, R; López-Duarte, M; López-Ibor, B; Maldonado, M; Melo, M; Moreno, MJ; Rives, S; Rodríguez, I; Tasso, M; Uriz, J; Verdeguer, A; Vivanco, JL	1
Chen, HR; Chen, P; Guo, Z; He, XP; Liu, B; Liu, D; Liu, XD; Wang, BR; Yang, K; Yao, YS	1
Ishida, T; Izawa, K; Kobayashi, S; Lin, SF; Tojo, A; Tsai, HJ; Umezawa, K; Watanabe, T	1
Abreu, MH; Gomez, RS; Resende, RG; Silva, ME; Teixeira, RG; Vasconcelos, Fde O	1
Ishikawa, M; Saito, T; Suzuki, M; Suzuki, Y; Tadokoro, K; Yagasaki, F; Yamaguchi, T	1
Badell, I; Camós, M; Estella, J; Gómez, P; López-Duarte, M; Navajas, A; Rives, S	1
Chang, BH; Druker, BJ; Jemal, AM; Thayer, M; Tyner, JW	1
Balduzzi, A; Berger, M; Fagioli, F; Favre, C; Lanino, E; Lo Nigro, L; Locatelli, F; Masetti, R; Messina, C; Prete, A; Rabusin, M; Rognoni, C; Zecca, M	1
Chosa, N; Fukudome, T; Hisakata, T; Horikawa, N; Ito, M; Kanda, Y; Kawano, N; Kugimiya, H; Okuda, S; Sakurai, R; Ueda, A; Yamashita, K; Yoshida, S	1
Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M	1
Binckebanck, A; Brück, P; Dührsen, U; Giagounidis, A; Hoelzer, D; Lange, T; Maier, J; Ottmann, OG; Pfeifer, H; Schmalzing, M; Schmidt, A; Serve, H; Stelljes, M; Wassmann, B; Wunderle, L; Wystub, S	1
Chen, X; Gong, Y; Lin, J; Liu, T; Xing, H; Yang, X	1
Camitta, BM; Carroll, WL; Chang, BH; Druker, BJ; Hunger, SP; Schultz, KR; Stork, L; Willis, SG; Winick, NJ	1
Fu, MW; Huang, J; Li, ZJ; Qi, JY; Qiu, LG; Xu, Y; Zhao, YZ; Zou, DH	1
Chen, ZM; Jin, J; Lou, JY; Meng, HT; Ni, WM; Qian, WB; Tong, HY; Wang, YG; Zhang, YF	1
Brandwein, JM; Gupta, V; Lipton, JH; Messner, HA; Minden, MD; Schimmer, AD; Schuh, AC; Thyagu, S; Xu, W; Yee, KW	1
Kantarjian, H; Liu-Dumlao, T; O'Brien, S; Ravandi, F; Thomas, DA	1
Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH; Zhang, YY; Zhao, XY	1
Cho, BS; Chung, NG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH	1
Abella, E; Amigo, ML; Barrios, M; Bravo, P; Brunet, S; García, O; González-Campos, J; Hernández-Rivas, JM; Montesinos, P; Ribera, JM	1
Gong, Y; Guo, Y; Lin, J; Shan, Q; Yang, X; Zhou, R	1
Aricò, M; Biondi, A; Campbell, M; Castor, A; De Lorenzo, P; Escherich, G; Gandemer, V; Li, CK; Lucchini, G; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stary, J; Valsecchi, MG; Vora, A	1
Thomas, D	1
Alpár, D; de Jong, D; Kajtár, B; Kereskai, L; Pajor, L; Savola, S; Szuhai, K; Yigittop, H	1
Cahn, JY; Cayuela, JM; Chalandon, Y; Delannoy, A; Dombret, H; Escoffre, M; Hayette, S; Huguet, F; Ifrah, N; Réa, D; Rousselot, P; Tanguy-Schmidt, A; Thomas, X; Vekemans, MC; Vernant, JP	1
Cortes, J; Santos, FP	1
Beelen, D; Bethge, W; Bornhäuser, M; Brück, P; Burmeister, T; Dengler, J; Dreger, P; Faul, C; Gökbuget, N; Gramatzki, M; Hoelzer, D; Horst, HA; Kiani, A; Kubuschok, B; Lange, E; Ottmann, OG; Pfeifer, H; Schäfer-Eckart, K; Schwerdtfeger, R; Serve, H; Stadler, M; Stelljes, M; Vucinic, V; Wassmann, B	1
Gong, YP; Guo, Y; Lin, J; Shan, QQ; Xing, HY; Yang, X; Zhou, RQ	1
Henze, G; Köchling, J; Rott, Y; Sagner, M; Schmidt, M; Ungefroren, H; Wittig, B	1
Dolgin, E	1
Fan, ZP; Huang, F; Jiang, QL; Ling, YW; Liu, QF; Sun, J; Zhai, X; Zhang, FH; Zhang, Y; Zhou, HS	1
Baccarani, M; Capdeville, R; Deininger, MW; Druker, BJ; Fernandes-Reese, S; Fischer, T; Gathmann, I; Goldman, JM; Gratwohl, A; Hochhaus, A; Hoelzer, D; O'Brien, SG; Ottmann, OG; Reiffers, J; Sawyers, CL; Schiffer, CA; Silver, RT; Tura, S	1
Alberti, D; Amabile, M; Baccarani, M; Capdeville, R; Guiducci, B; Isidori, A; Malagola, M; Martinelli, G; Piccaluga, PP; Tura, S; Visani, G	1
Ikeda, Y; O'Brien, SG; Okamoto, S; Sato, N; Takayama, N	1
Atta, J; Bruck, P; Gehrke, B; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Petershofen, EK; Pfeifer, H; Scheuring, UJ; Wassmann, B	1
Gökbuget, N; Hoelzer, D; Ottmann, OG	1
Binckebanck, A; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Klein, SA; Martin, H; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B	1
Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P	1
Buss, EC; Fruehauf, S; Goerner, M; Ho, AD; Schad, M; Topaly, J; Zeller, WJ	1
Goi, K; Inukai, T; Kagami, K; Kayagaki, N; Koyama-Okazaki, T; Nakazawa, S; Nemoto, A; Okumura, K; Sato, H; Sugita, K; Suzuki, T; Takahashi, K; Uno, K; Yagita, H; Yamaguchi, N	1
Cervantes, F; Hernández-Boluda, JC	1
Avigdor, A; Ben-Bassat, I; Hardan, I; Kröger, N; Nagler, A; Rowe, JM; Shimoni, A; Yeshurun, M; Zander, AR	1
Belinchon-Romero, I; Fernandez-Abellan, P; Pascual-Ramirez, JC; Rivas, C; Sanchez-Gonzalez, B; Vegara-Aguilera, G	1
Hoelzer, D; Ottmann, OG; Wassmann, B	2
Ottmann, OG; Wassmann, B	2
Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Jones, LC; Koeffler, HP; Komor, M; Ottmann, OG; Wassmann, B	1
Hehlmann, R; Larson, R; Schiffer, CA	1
Gulley, ML; Nashed, AL; Rao, KW	1
Brandwein, J; Gupta, V; Kamel-Reid, S; Lipton, JH; Messner, HA; Minden, MD	1
Chiba, H; Hirayama, Y; Kato, J; Maeda, M; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y	1
Brück, P; Gehrke, B; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Petershofen, EK; Pfeifer, H; Scheuring, UJ; Wassmann, B	1
Cherrier-De Wilde, S; Delannoy, A; Hagemeijer, A; Rack, K; Vannuffel, P	1
Beissert, T; Güller, S; Hoelzer, D; Li, JE; Ottmann, OG; Puccetti, E; Ruthardt, M	1
Bornmann, WG; Clarkson, B; Duyster, J; Li, W; Miller, WT; Peschel, C; Sänger, J; Veach, DR; von Bubnoff, N	1
Jin Huh, H; Lee, M; Myong Seong, C; Soon Chung, W; Won Huh, J	1
Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B	1
Baskaynak, G; Bonin, Mv; Bornhäuser, M; Dörken, B; Ehninger, G; Jenke, A; Kreuzer, KA; le Coutre, P; Leopold, T; Ottmann, O; Pursche, S; Schleyer, E	1
Bloomfield, CD; Carroll, AJ; Dodge, RK; Larson, RA; Mrózek, K; Stewart, CC; Tantravahi, R; Vardiman, JW; Wetzler, M	1
Amabile, M; Baccarani, M; Gaitani, S; Malagola, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Soverini, S; Visani, G	1
Bujassoum, S; Lipton, JH; Rifkind, J	1
Asano, S; Bai, Y; Chen, M; Harata, M; Iseki, T; Izawa, K; Kobayashi, S; Maruyama, K; Nagamura, F; Nakazawa, S; Ooi, J; Soda, Y; Sugita, K; Takahashi, S; Takahashi, TA; Takizawa, T; Tani, K; Tojo, A; Tomonari, A; Tsuji, T; Uchimaru, K	1
Hoelzer, D; Hofmann, WK; Komor, M; Ottmann, OG	1
Curtin, PT; Druker, BJ; Ford, JM; Leis, JF; Maziarz, RT; Peng, B; Schubach, S; Stepan, DE	1
Gross, G; Kretz, O; Schumacher, MM; Weiss, HM	1
Bando, S; Fujita, S; Hato, T; Hojo, N; Kohno, M; Niiya, Y; Sakai, I; Takada, K; Tamura, T; Yakushijin, Y; Yamanouchi, J; Yasukawa, M	1
Jinnai, I; Kawai, Y; Matsuo, K; Miyawaki, S; Naoe, T; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Towatari, M; Usui, N; Yagasaki, F; Yanada, M	1
Robak, T	1
Amabile, M; Baccarani, M; Malagola, M; Martinelli, G; Pane, F; Paolini, S; Piccaluga, PP; Rondoni, M; Russo, D; Visani, G	1
Le, QH; Tavernier, E; Thomas, X	1
Anderlini, P; Champlin, RE; Giralt, S; Hicks, K; Ippoliti, C; Sheth, S	1
Feldhahn, N; Hofmann, WK; Klein, F; Mooster, JL; Müschen, M; Sprangers, M; Wartenberg, M; Wernet, P	1
Bessho, F; Hayashi, Y; Hongo, T; Ida, K; Kawaguchi, H; Kobayashi, M; Koh, K; Park, MJ; Taketani, T; Taki, T; Takita, J; Yoshino, H	1
Cassileth, PA; Morgensztern, D; Raez, LE; Rosado, MF; Santos, ES	1
Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS	1
Hawkins, LM; Jayanthan, AA; Narendran, A	1
Azam, M; Breitenstein, W; Brüggen, J; Callahan, L; Catley, L; Cavazza, C; Cowan-Jacob, SW; Daley, GQ; Fabbro, D; Fendrich, G; Gilliland, DG; Griffin, JD; Hall-Meyers, E; Huntly, B; Kung, AL; Manley, PW; Mestan, J; Mohammed, A; Neuberg, D; Ray, A; Weisberg, E; Wright, RD	1
Cools, J; De Keersmaecker, K; Graux, C; Hagemeijer, A; Maertens, J; Marynen, P; Mentens, N; Odero, MD; Somers, R; Vandenberghe, P; Wlodarska, I	1
Berger, U; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Riehm, B; Schoch, C; Schwindel, U	1
Akiyama, H; Kobayashi, T; Ohashi, K; Sakai, M; Sakamaki, H; Yamashita, T	1
Jones, RL; Judson, IR	1
Duch-Samper, A; Hurtado-Sarrió, M; Martínez-Dominguez, JA; Menezo-Rozalén, JL; Senent-Peris, ML; Taboada-Esteve, J	1
Lovas, N; Poros, A	1
Brandwein, JM; Chun, K; Gupta, V; Kamel-Reid, S; Lipton, JH; Messner, HA; Minden, MD; Schimmer, AD; Schuh, AC; Wells, RA; Yi, QL	1
Aleskog, A; Barbany, G; Björnberg, A; Hallböök, H; Larsson, R; Lindhagen, E; Sundström, C	1
Chi, HS; Choi, SJ; Jang, S; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Seo, EJ; Seol, M	1
Alland, L; Arlinghaus, RB; Beran, M; Cortes, J; Dugan, M; Estrov, Z; Giles, F; Golemovic, M; Kantarjian, H; Manley, P; Manshouri, T; Sun, T; Verstovsek, S	1
Jones, LK; Saha, V	1
Ashihara, E; Fujiyama, Y; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; Ottmann, OG; Sato, K; Segawa, H; Yokota, A; Yuasa, T	1
Cho, GJ; Chung, JS; Shin, HJ	1
Domracheva, EV; Isaev, VG; Kliasova, GA; Liubimova, LS; Mendeleeva, LP; Misiurin, AV; Parovichnikova, EN; Rossiev, VA; Rukavitsyn, OA; Savchenko, VG; Tikhonova, LIu; Turkina, AG; Verniuk, MA; Vinogradova, OA; Vorob'ev, IA	1
Luppi, M; Marasca, R; Martinelli, S; Potenza, L; Riva, G; Torelli, G	1
Larson, RA	1
Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Igarashi, T; Lundqvist, A; Rezvani, K; Savani, BN; Srinivasan, R; Takahashi, Y	1
Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Piccirillo, N; Reddiconto, G; Sica, S; Sorà, F	1
Akiyama, H; Emi, N; Jinnai, I; Kobayashi, T; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M	1
Dumur, CI; Ferreira-Gonzalez, A; Fossey, SC; Garrett, CT; Vnencak-Jones, CL	1
Choufi, B; Dombret, H; Dupriez, B; Huguet, F; Legros, L; Maury, S; Ojeda-Uribe, M; Pigneux, A; Raffoux, E; Rea, D; Recher, C; Reman, O; Rousselot, P; Royer, B; Stéphane, D; Thomas, X; Turlure, P; Vigier, M	1
Hong-eng, S; Limsuwan, A; Pakakasama, S; Rochanawutanon, M	1
Koseki, M; Matsue, K; Takeuchi, M; Uryu, H	1
Ishii, Y; Kimura, Y; Ohyashiki, K; Shoji, N	1
Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Jones, D; Jones, R; Kantarjian, HM	1
Beck, J; Beelen, DW; Binckebanck, A; Bornhäuser, M; Brück, P; Ganser, A; Goekbuget, N; Gschaidmeier, H; Haas, R; Hoelzer, D; Kanz, L; Kaufmann, M; Lenz, G; Ottmann, OG; Perz, J; Pfeifer, H; Reichle, A; Reutzel, R; Schmid, M; Schwartz, S; Stelljes, M; Wassmann, B	1
Blackwood-Chirchir, MA; Bleickardt, E; Chen, TT; Cortes, J; Decillis, AP; Donato, N; Huang, F; Iyer, V; Kantarjian, H; Nicaise, C; Nicoll, J; O'Brien, S; Paquette, R; Sawyers, CL; Shah, NP; Talpaz, M	1
Albitar, M; Alland, L; Bhalla, K; Bochinski, K; Cortes, J; Dugan, M; Giles, F; Griffin, JD; Hochhaus, A; Hoelzer, D; Kantarjian, H; Manley, P; Mietlowski, W; O'Brien, S; Ottmann, OG; Rae, P; Tanaka, C; Wassmann, B; Wunderle, L	1
Druker, BJ	1
Colson, YL; Marty, FM; Paul, S	1
Naithani, R; Panigrahi, I	1
Huang, M; Liu, WL; Ran, D; Sun, HY; Zhang, YC; Zhou, JF	1
Béné, MC; Berthaud, P; Bilhou-Nabera, C; Bologna, S; Buzyn, A; Caillères, S; Castaigne, S; Coso, D; Darre, S; Delabesse, E; Delain, M; Delannoy, A; Dombret, H; Dubruille, V; Fohrer, C; Garban, F; Isnard, F; Legrand, O; Lhéritier, V; Raby, P; Raffoux, E; Reman, O; Rigal-Huguet, F; Sonet, A; Thomas, X; Turlure, P	1
Kovacsovics, T; Maziarz, RT	1
Selleslag, D	1
Asakura, H; Miyamura, K; Murayama, T; Nagai, K; Nakao, S; Shibayama, M; Shimadoi, S; Sugimori, C; Takami, A; Takemoto, K; Yoshida, T	1
Au, WY; Chan, E; Lie, AK	1
Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F	1
Naoe, T; Yanada, M	1
Hoelzer, D	1
Ambrosetti, A; Annino, L; Baccarani, M; Bertieri, R; Cimino, G; Di Raimondo, F; Elia, L; Fazi, P; Ferrara, F; Foà, R; Mandelli, F; Martinelli, G; Meloni, G; Pagano, L; Quarta, G; Rege-Cambrin, G; Vignetti, M	1
Benson, RE; Farthing, PM; Loescher, AR; North, S; Payne, M; Rodd, HD	1
Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N	1
Li, S	2
Aulitzky, WE; Beneke, H; Cross, NC; Del Valle, F; Diecker, F; Döhner, H; Erben, P; Haferlach, C; Haferlach, T; Hehlmann, R; Hochhaus, A; Hodges, E; Metzgeroth, G; Mix, J; Müller, L; Müller, MC; Müller-Hermelink, K; Popp, H; Reiter, A; Schmitz, N; Schnittger, S; Schuld, P; Schulte, C; Score, J; Siebert, R; Walz, C; Whittaker, SJ; Wittkowsky, G	1
Binckebanck, A; Brück, P; Hochhaus, A; Hoelzer, D; Lange, T; Oldenburg, J; Ottmann, OG; Pavlova, A; Pfeifer, H; Wassmann, B; Wunderle, L; Wystub, S	1
Binckebanck, A; Dührsen, U; Giagounidis, A; Hoelzer, D; Ottmann, OG; Pfeifer, H; Schmalzing, M; Stelljes, M; Wassmann, B; Wunderle, L	1
Apperley, JF; Chaidos, A; Kanfer, E	1
Brocca, MC; Coppi, MR; Mele, G; Melpignano, A; Pinna, S; Quarta, G; Romano, A	1
Yanada, M	1
Katayama, N; Nishii, K; Ryuu, H; Sakakura, M; Tsukada, T	1
Angelucci, E; Barbui, T; Bassan, R; Fabris, P; Grassi, A; Guerini, V; Intermesoli, T; Lambertenghi-Deliliers, G; Micò, C; Oldani, E; Peruta, B; Rambaldi, A; Rossi, G; Salvi, A; Spinelli, O; Tosi, M; Zanotti, MC	1
Apanovitch, AM; Coutre, S; Dombret, H; Gollerkeri, A; Guilhot, F; Hochhaus, A; Larson, RA; Martinelli, G; Ottmann, O; Radich, J; Rege-Cambrin, G; Simonsson, B	1
Hishida, A; Katagiri, T; Nakamura, Y; Naoe, T; Ohno, R; Sugiura, I; Takeuchi, J; Tsuruo, T; Usui, N; Yanada, M; Zembutsu, H	1
Sherr, CJ; Williams, RT	1
Martinelli, G; Paolini, S; Piccaluga, PP	1
den Besten, W; Sherr, CJ; Williams, RT	1
Brodzik, F; Mehdi, S; Pasquale, D; Ramanarayanan, J	1
Dorshkind, K; Witte, ON	1
Sawyers, CL	2
Chiusolo, P; Farina, G; Fiorini, A; Leone, G; Reddiconto, G; Sica, S; Sorà, F	1
Agirre, X; Andreu, EJ; Calasanz, MJ; Cordeu, L; Gárate, L; Heiniger, A; Jiménez-Velasco, A; José-Eneriz, ES; Montiel-Duarte, C; Prósper, F; Román-Gómez, J; Torres, A	1
Botteman, MF; Carpiuc, KT; Feng, W; Hay, JW; Stephens, JM	1
Thomas, X	1
Thomas, DA	1
Cross, SA; Lyseng-Williamson, KA	1
Wassmann, B	1
Swords, R	1
Brandwein, J	1
Bermúdez, M; Calle, D; Fuster, JL; Galera, A; Llinares, ME; Ortuño, FJ	1
Albitar, M; Bhalla, K; Cortes, J; Faraji, H; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; O'Brien, S; Ottmann, O	1
Steinberg, M	1
Ichikawa, N; Kobayashi, H; Shimizu, I; Sumi, M; Ueno, M; Yotsumoto, M	1
Booth, B; Brave, M; Bullock, J; Farrell, A; Gobburu, J; Goodman, V; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kenna, L; Men, A; Morse, D; Noory, C; Pazdur, R; Pope, S; Ramchandani, R; Saber, H; Sridhara, R; Timmer, W	1
Akiyama, H; Jinnai, I; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M	1
Capdeville, R; Ford, JM; Gathmann, I; Hatfield, A; Krahnke, T; Van Hoomissen, I	1
Cortes, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Vega-Ruiz, A	1
Binckebanck, A; Debatin, J; Dugan, M; Erben, P; Ernst, T; Härtel, N; Hehlmann, R; Hochhaus, A; Holm-Eriksen, S; Konig, H; La Rosée, P; Mueller, MC; Ottmann, OG; Shou, Y; Wunderle, L	1
Cuvelier, GD; Dix, DB; Ford, JC; Vitali, AM	1
Dombret, H; Thomas, X	1
Cobanoglu, U; Omay, SB; Ovali, E; Sonmez, M	1
Buttignol, S; Candoni, A; Fanin, R; Simeone, E; Sperotto, A; Tiribelli, M	1
Arlinghaus, RB; Beran, M; Cao, X; Estrov, Z; Jeha, S; Jin, G; Kantarjian, H; Lydon, NB; O'Brien, S; Talpaz, M	1
Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Reese, SF; Resta, DJ; Sawyers, CL; Talpaz, M	1
Jinnai, I; Kawaguchi, Y; Kuriyama, K; Matsuo, T; Nagai, K; Tomonaga, M; Yagasaki, F; Yakata, Y	1
Nakajima, A; Ohyashiki, K; Tauchi, T	1
Baron, F; Beguin, Y; Fillet, G; Frère, P	1
Press, RD	1
Banerji, L; Deininger, MW; Goldman, JM; Köhler, T; Lam, EW; Mahon, FX; Melo, JV; Parada, Y; Peters, G; Vieira, SA	1
Kalaycio, ME	1
Dann, EJ; Fineman, R; Rowe, JM	1
Griffin, JD	1
de Vos, S; Elashoff, D; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Koeffler, HP; Ottmann, OG	1
de Vos, S; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Jones, LC; Koeffler, HP; Lemp, NA; Ottmann, OG	1
Antman, KH; Savage, DG	1
Hochhaus, A	1
Hoelzer, D; Ottmann, OG	1
Arthur, C; Branford, S; Grigg, A; Herrmann, R; Hughes, TP; Lynch, KP; Rudzki, Z; Taylor, K; Walsh, S	1
Akiyama, H; Mikoshiba, M; Ohashi, K; Sakamaki, H; Sugimoto, K	1

Reviews

69 review(s) available for imatinib mesylate and Acute Lymphoid Leukemia

Article	Year
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA oncology, 2022, 09-01, Volume: 8, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
[Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023, Jan-14, Volume: 44, Issue:1 Topics: Humans; Imatinib Mesylate; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators	2023
Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. BMJ open, 2021, 01-19, Volume: 11, Issue:1 Topics: Child; Disease-Free Survival; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2021
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best practice & research. Clinical haematology, 2017, Volume: 30, Issue:3 Topics: Antineoplastic Agents; Dasatinib; Disease Management; Fusion Proteins, bcr-abl; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Mutation; Philadelphia Chromosome; Precision Medicine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Survival Analysis; Transplantation, Homologous	2017
How is the Ph-like signature being incorporated into ALL therapy? Best practice & research. Clinical haematology, 2017, Volume: 30, Issue:3 Topics: Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Janus Kinases; Molecular Targeted Therapy; Nitriles; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Survival Analysis; Transplantation, Homologous	2017
Pharmacogenomic approaches for tailored anti-leukemic therapy in children. Current medicinal chemistry, 2013, Volume: 20, Issue:17 Topics: Alkaloids; Antineoplastic Agents; Benzamides; Child; Glucocorticoids; Hepatic Veno-Occlusive Disease; Humans; Imatinib Mesylate; Mercaptopurine; Methotrexate; Nucleotides; Pharmacogenetics; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thioguanine; Vincristine	2013
[Anticancer drug adherence]. Bulletin du cancer, 2013, Volume: 100, Issue:5 Topics: Administration, Oral; Age Factors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Medication Adherence; Neoplasms; Physician's Role; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Socioeconomic Factors	2013
[Acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Humans; Imatinib Mesylate; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult	2014
Current and future management of Ph/BCR-ABL positive ALL. Expert review of anticancer therapy, 2014, Volume: 14, Issue:6 Topics: Age of Onset; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytogenetic Analysis; Disease Management; Drug Resistance, Neoplasm; Drugs, Investigational; Forecasting; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Incidence; Molecular Targeted Therapy; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome	2014
[Current treatment of philadelphia chromosome-positive acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Molecular Typing; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Young Adult	2014
[Current treatment of pediatric acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Topic; Cytarabine; Dexamethasone; Drug Discovery; Humans; Imatinib Mesylate; Induction Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines	2014
[Treatment of adult acute lymphoblastie leukemia with eosinophilia and abnormality of PDGFRA by autologous hematopoietic stem cell transplantation and imatinib: one case report and literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:10 Topics: Adult; Eosinophilia; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor alpha	2015
Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. British journal of haematology, 2016, Volume: 172, Issue:6 Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2016
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert opinion on drug discovery, 2016, Volume: 11, Issue:11 Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2016
Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission? Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:4 Topics: Allografts; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2016
Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Current oncology reports, 2008, Volume: 10, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Female; Humans; Imatinib Mesylate; Immunotherapy; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome	2008
Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9 Topics: Adult; Algorithms; Benzamides; Disease-Free Survival; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Survival Rate; Transplantation, Homologous	2008
[Management of acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10 Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Thiazoles	2008
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. British journal of haematology, 2009, Volume: 145, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation Conditioning; Treatment Outcome	2009
First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Current opinion in oncology, 2009, Volume: 21 Suppl 1 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dasatinib; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Outcome	2009
Old disease, new targets. Part-II, haematological malignancies. JPMA. The Journal of the Pakistan Medical Association, 2009, Volume: 59, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Costs; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Time Factors	2009
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2010, Volume: 51, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2009, Volume: 50 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2009
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase. Current hematologic malignancy reports, 2007, Volume: 2, Issue:2 Topics: Apoptosis; Benzamides; Cell Differentiation; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species	2007
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Current hematologic malignancy reports, 2007, Volume: 2, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Stem Cell Transplantation; Survival Analysis; Treatment Outcome	2007
Imatinib mesylate in children and adolescents with cancer. Pediatric blood & cancer, 2010, Jul-15, Volume: 55, Issue:1 Topics: Adolescent; Benzamides; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2010
Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Current hematologic malignancy reports, 2010, Volume: 5, Issue:4 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Vincristine	2010
Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. Expert review of hematology, 2010, Volume: 3, Issue:6 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Thiazoles; Transplantation, Homologous	2010
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer, 2011, Apr-15, Volume: 117, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation	2011
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2011
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Current hematologic malignancy reports, 2011, Volume: 6, Issue:3 Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous	2011
Tyrosine kinase inhibitors in hematological malignancies. Postepy higieny i medycyny doswiadczalnej (Online), 2011, Dec-05, Volume: 65 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2011
Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Current oncology reports, 2012, Volume: 14, Issue:5 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Neoplasm, Residual; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles	2012
Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:16 Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2012
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Seminars in hematology, 2002, Volume: 39, Issue:4 Suppl 3 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Mas; Pyrimidines; Treatment Outcome	2002
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. Drugs of today (Barcelona, Spain : 1998), 2002, Volume: 38, Issue:9 Topics: Antineoplastic Agents; Benzamides; Biological Availability; Clinical Trials as Topic; Half-Life; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Pyrimidines	2002
Imatinib for relapsed BCR/ABL positive leukemias. Annals of hematology, 2002, Volume: 81 Suppl 2 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Stem Cell Transplantation	2002
Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. Best practice & research. Clinical haematology, 2002, Volume: 15, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzamides; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Salvage Therapy	2002
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia, 2003, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Benzamides; Biomarkers; Biomarkers, Tumor; Blast Crisis; Bone Marrow Examination; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Life Tables; Neoplasm Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis	2003
Clinical applications of BCR-ABL molecular testing in acute leukemia. The Journal of molecular diagnostics : JMD, 2003, Volume: 5, Issue:2 Topics: Benzamides; Blotting, Southern; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Models, Genetic; Oligonucleotide Array Sequence Analysis; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors	2003
Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission. Leukemia, 2003, Volume: 17, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2003
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. American journal of hematology, 2003, Volume: 74, Issue:3 Topics: Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction	2003
Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2004, Volume: 45, Issue:4 Topics: Benzamides; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Mutation; Oncogene Proteins v-abl; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2004
Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs & aging, 2004, Volume: 21, Issue:12 Topics: Adult; Aged; Aging; Antineoplastic Agents; Benzamides; Female; Geriatrics; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Phenotype; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Treatment Outcome	2004
[Acute lymphoblastic leukemia in elderly: prognosis and treatment]. Bulletin du cancer, 2004, Volume: 91, Issue:9 Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Liposomes; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2004
The development and application of imatinib. Expert opinion on drug safety, 2005, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2005
[The role of imatinib in the treatment of acute lymphoid leukemias]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome	2005
Philadelphia positive acute lymphoblastic leukaemia of childhood. British journal of haematology, 2005, Volume: 130, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous	2005
[New therapeutic strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Imatinib mesylate: A designer drug. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Benzamides; Eosinophilia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2006
Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation. Current oncology reports, 2006, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous	2006
Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leukemia & lymphoma, 2006, Volume: 47, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Advances in the management of Ph-positive ALL. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:11 Topics: Aging; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2006
Src kinase signaling in leukaemia. The international journal of biochemistry & cell biology, 2007, Volume: 39, Issue:7-8 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Survival; Enzyme Activation; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Mice; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Signal Transduction; src-Family Kinases	2007
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:2 Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous	2007
[Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jan-28, Volume: 65 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2007
The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Advances in experimental medicine and biology, 2007, Volume: 604 Topics: Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Interleukin-7; Mice; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Suppressor Protein p14ARF	2007
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer, 2007, Sep-15, Volume: 110, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Thiazoles; Treatment Outcome	2007
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:16 Topics: Antineoplastic Agents; Benzamides; Costs and Cost Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Stem Cell Transplantation	2007
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bulletin du cancer, 2007, Volume: 94, Issue:10 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles	2007
Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology. American Society of Hematology. Education Program, 2007 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation	2007
Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Treatment Outcome	2007
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical therapeutics, 2007, Volume: 29, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Chemical; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiazoles	2007
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia & lymphoma, 2008, Volume: 49, Issue:1 Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Signal Transduction; src-Family Kinases	2008
Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia & lymphoma, 2008, Volume: 49, Issue:7 Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2008
Chronic myelogenous leukemia: the news you have and haven't heard. Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:11 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials as Topic; Diagnosis, Differential; Enzyme Inhibitors; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2001
Imatinib mesylate--a new oral targeted therapy. The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance; Gastrointestinal Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma	2002
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]. Deutsche medizinische Wochenschrift (1946), 2002, Mar-01, Volume: 127, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors	2002
The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities. The hematology journal : the official journal of the European Haematology Association, 2002, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2002

Trials

66 trial(s) available for imatinib mesylate and Acute Lymphoid Leukemia

Article	Year
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood advances, 2022, 01-25, Volume: 6, Issue:2 Topics: Acute Disease; Adult; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence	2022
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. The Lancet. Haematology, 2023, Volume: 10, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dasatinib; Female; Humans; Imatinib Mesylate; Male; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome	2023
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA oncology, 2020, 03-01, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Child; Child, Preschool; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Treatment Outcome	2020
Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. British journal of haematology, 2020, Volume: 190, Issue:1 Topics: Adult; Aged; Ambulatory Care; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Coronavirus Infections; COVID-19; Female; Humans; Imatinib Mesylate; Italy; Male; Middle Aged; Pandemics; Philadelphia Chromosome; Pneumonia, Viral; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2020
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Survival Rate	2018
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica, 2019, Volume: 104, Issue:1 Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Leukocyte Count; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate	2019
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8 Topics: Adolescent; Allografts; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Survival Rate	2019
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer, 2019, 08-15, Volume: 125, Issue:16 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Incidence; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome; Young Adult	2019
Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatric blood & cancer, 2013, Volume: 60, Issue:8 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Transplantation, Homologous	2013
[Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study]. Zhonghua yi xue za zhi, 2013, Feb-26, Volume: 93, Issue:8 Topics: Adolescent; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2013
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult	2013
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leukemia & lymphoma, 2015, Volume: 56, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Nuclear Proteins; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Verapamil; Vincristine; Young Adult	2015
Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:8 Topics: Adult; Aged; Autografts; Benzamides; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Sweden; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04. Cancer medicine, 2015, Volume: 4, Issue:5 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Japan; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, Volume: 100, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dexamethasone; Doxorubicin; Follow-Up Studies; Humans; Imatinib Mesylate; Induction Chemotherapy; Maintenance Chemotherapy; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retreatment; Risk Factors; Treatment Outcome; Vincristine; Young Adult	2015
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica, 2015, Volume: 100, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Middle Aged; Mutation; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous	2015
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 2015, Jun-11, Volume: 125, Issue:24 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Treatment Outcome; Young Adult	2015
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American journal of hematology, 2015, Volume: 90, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Benzamides; Blast Crisis; Diarrhea; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nitriles; Piperazines; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Survival Analysis; Treatment Outcome	2015
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Vincristine	2015
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood cancer journal, 2016, 12-09, Volume: 6, Issue:12 Topics: Adolescent; Adult; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Rituximab; Transplantation, Homologous; Treatment Outcome; Young Adult	2016
Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. American journal of hematology, 2017, Volume: 92, Issue:4 Topics: Adolescent; Adult; Consolidation Chemotherapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult	2017
The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer, 2009, Feb-01, Volume: 115, Issue:3 Topics: Adolescent; Adult; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Stem Cell Transplantation; Time Factors	2009
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC cancer, 2009, Jan-13, Volume: 9 Topics: Acute Disease; Adolescent; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cortisone; Female; Humans; Imatinib Mesylate; Infant; Leukocyte Count; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Recurrence; Treatment Outcome; Vincristine; Young Adult	2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL T Blood, 2009, May-07, Volume: 113, Issue:19 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult	2009
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase Blood, 2009, May-21, Volume: 113, Issue:21 Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult	2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. International journal of hematology, 2009, Volume: 89, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Treatment Outcome	2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-20, Volume: 27, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult	2009
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica, 2010, Volume: 95, Issue:1 Topics: Adolescent; Adult; Benzamides; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Pyrimidines; Remission Induction; Stem Cell Transplantation; Survival Rate; Treatment Outcome; Young Adult	2010
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-01, Volume: 27, Issue:31 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Young Adult	2009
Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood, 2010, Feb-25, Volume: 115, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow Cells; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunologic Memory; Interferon-gamma; Interleukin-2; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; T-Lymphocytes, Cytotoxic; Time Factors	2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. American journal of hematology, 2010, Volume: 85, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; src-Family Kinases; Thiazoles; Young Adult	2010
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-01, Volume: 28, Issue:22 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Italy; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Stem Cell Transplantation	2010
Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Chinese medical journal, 2011, Volume: 124, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Pyrimidines; Transplantation, Homologous; Young Adult	2011
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica, 2011, Volume: 96, Issue:8 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Child; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2011
Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative G British journal of haematology, 2011, Volume: 154, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Spain; Tissue Donors; Transplantation, Homologous; Treatment Outcome	2011
[Application of imatinib plus Hyper-CVAD chemotherapy regimen in patients with Ph chromosome positive acute lymphocytic leukemia]. Zhonghua yi xue za zhi, 2011, May-31, Volume: 91, Issue:20 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult	2011
[Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:10 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Transplantation, Homologous; Young Adult	2011
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. Journal of hematology & oncology, 2012, Jun-08, Volume: 5 Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult	2012
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. British journal of haematology, 2012, Volume: 159, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Imatinib Mesylate; Male; Mercaptopurine; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vincristine; Young Adult	2012
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. The Lancet. Oncology, 2012, Volume: 13, Issue:9 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Infant; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Stem Cell Transplantation; Survival Rate	2012
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1 Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous; Unrelated Donors	2013
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia, 2013, Volume: 27, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Patient Compliance; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Survival Analysis; Young Adult	2013
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 2002, Sep-15, Volume: 100, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Salvage Therapy; Survival Analysis	2002
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood, 2003, Jan-01, Volume: 101, Issue:1 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Disease-Free Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Salvage Therapy	2003
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia, 2002, Volume: 16, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Salvage Therapy; Survival Analysis; Therapeutic Equivalency; Transplantation, Homologous; Treatment Outcome	2002
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 2003, Volume: 17, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome	2003
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia, 2003, Volume: 17, Issue:9 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Fusion Proteins, bcr-abl; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Treatment Outcome	2003
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & lymphoma, 2004, Volume: 45, Issue:4 Topics: Adult; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Tissue Distribution; Treatment Outcome	2004
In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. British journal of clinical pharmacology, 2004, Volume: 58, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Dogs; Female; Humans; Imatinib Mesylate; Macaca fascicularis; Male; Mice; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Pyrimidines; Rats; Rats, Wistar	2004
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood, 2004, Dec-01, Volume: 104, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Time Factors; Transplantation, Homologous; Treatment Outcome	2004
The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 2005, May-01, Volume: 105, Issue:9 Topics: Adolescent; Adult; Algorithms; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Survival Analysis; Transplantation, Homologous; Treatment Outcome	2005
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer, 2005, Apr-15, Volume: 103, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2005
Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 2005, Volume: 19, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Treatment Outcome	2005
Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone marrow transplantation, 2005, Volume: 36, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Purging; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Autologous	2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Feasibility Studies; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome	2006
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 2006, Sep-01, Volume: 108, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Drug Administration Schedule; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Pyrimidines; Remission Induction; Survival Analysis; Transcription, Genetic; Treatment Outcome	2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England journal of medicine, 2006, Jun-15, Volume: 354, Issue:24 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neutropenia; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. The New England journal of medicine, 2006, Jun-15, Volume: 354, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2006
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, Feb-15, Volume: 109, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Transplantation, Homologous	2007
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adu Blood, 2007, May-01, Volume: 109, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Steroids; Survival Rate	2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Codon; Dasatinib; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Structure-Activity Relationship; Thiazoles	2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia, 2007, Volume: 21, Issue:6 Topics: Acute Disease; Adult; Aged; Benzamides; Disease-Free Survival; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Nucleophosmin; Oncogene Proteins, Fusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction	2007
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer, 2007, May-15, Volume: 109, Issue:10 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate	2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, Oct-01, Volume: 110, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Time Factors	2007
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica, 2008, Volume: 93, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Pyrimidines; Recurrence; Survival Rate; Transplantation, Homologous	2008
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine, 2001, Apr-05, Volume: 344, Issue:14 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction	2001

Other Studies

279 other study(ies) available for imatinib mesylate and Acute Lymphoid Leukemia

Article	Year
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study. The Korean journal of internal medicine, 2021, Volume: 36, Issue:6 Topics: Asparaginase; Humans; Imatinib Mesylate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies	2021
Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. Scientific reports, 2021, 11-04, Volume: 11, Issue:1 Topics: Animals; Cell Line, Tumor; Dasatinib; Eukaryotic Initiation Factor-4F; Imatinib Mesylate; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases	2021
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia. Cancer science, 2022, Volume: 113, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 2 Subunit; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mutation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy. Journal of adolescent and young adult oncology, 2022, Volume: 11, Issue:6 Topics: Adult; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy	2022
Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia. Pediatrics international : official journal of the Japan Pediatric Society, 2022, Volume: 64, Issue:1 Topics: Acute Disease; Early Diagnosis; Humans; Imatinib Mesylate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators	2022
Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance. Journal of pediatric hematology/oncology, 2022, Apr-01, Volume: 44, Issue:3 Topics: Blast Crisis; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction	2022
[Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia]. Revista medica de Chile, 2021, Volume: 149, Issue:9 Topics: Adolescent; Adult; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Young Adult	2021
Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia. Anales de pediatria, 2022, Volume: 96, Issue:4 Topics: Acute Disease; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2022
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system. International journal of hematology, 2022, Volume: 116, Issue:4 Topics: Antineoplastic Agents; Cell Line; CRISPR-Associated Protein 9; CRISPR-Cas Systems; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nucleotides; Oligodeoxyribonucleotides; Philadelphia Chromosome; Poly (ADP-Ribose) Polymerase-1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; RNA, Guide, Kinetoplastida	2022
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:10 Topics: Antibodies, Bispecific; Cytokines; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood advances, 2022, 09-27, Volume: 6, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imatinib Mesylate; Imidazoles; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Recurrence; Young Adult	2022
Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic Pathology oncology research : POR, 2022, Volume: 28 Topics: Adolescent; Antineoplastic Agents; Benzamides; Gene Fusion; Humans; Imatinib Mesylate; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines	2022
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. PloS one, 2022, Volume: 17, Issue:10 Topics: Adult; Aged; Boron Compounds; Bortezomib; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Glycine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors	2022
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia? Hematology. American Society of Hematology. Education Program, 2022, 12-09, Volume: 2022, Issue:1 Topics: Adult; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors	2022
FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report. Cancer reports (Hoboken, N.J.), 2023, Volume: 6, Issue:1 Topics: Child; Eosinophilia; Humans; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha	2023
Acute kidney injury and delayed methotrexate clearance in an adult patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia treated with imatinib. European journal of hospital pharmacy : science and practice, 2023, Volume: 30, Issue:5 Topics: Acute Kidney Injury; Adult; Female; Humans; Imatinib Mesylate; Methotrexate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2023
BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists. Journal of translational medicine, 2023, 02-10, Volume: 21, Issue:1 Topics: Animals; bcl-2-Associated X Protein; Imatinib Mesylate; Mice; Oligodeoxyribonucleotides; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Toll-Like Receptor 9	2023
Establishment and Characterization of an Acute Lymphocytic Leukemia Cell Line Expressing CD13 and CD33 with a Complex Philadelphia Translocation. Internal medicine (Tokyo, Japan), 2023, Volume: 62, Issue:5 Topics: Adult; Cell Line; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sialic Acid Binding Ig-like Lectin 3	2023
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison. Advances in therapy, 2023, Volume: 40, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2023
Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China. BMC health services research, 2023, Jun-19, Volume: 23, Issue:1 Topics: Child; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2023
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer science, 2019, Volume: 110, Issue:10 Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dasatinib; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult	2019
Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Leukemia & lymphoma, 2020, Volume: 61, Issue:2 Topics: Adolescent; Humans; Imatinib Mesylate; Male; Oncogene Proteins, Fusion; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators; Transcription Factors; Treatment Outcome	2020
Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway. Oncology reports, 2020, Volume: 43, Issue:2 Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2020
Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA oncology, 2020, 03-01, Volume: 6, Issue:3 Topics: Acute Disease; Child; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2020
Dasatinib versus imatinib for childhood acute lymphocytic leukaemia. The Lancet. Oncology, 2020, Volume: 21, Issue:2 Topics: Child; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2020
Dasatinib versus imatinib in paediatric ALL. Nature reviews. Clinical oncology, 2020, Volume: 17, Issue:4 Topics: Child; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2020
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. British journal of haematology, 2020, Volume: 189, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dasatinib; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies	2020
Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 2021, 03-01, Volume: 43, Issue:2 Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, B-Cell; Male; Methotrexate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Young Adult	2021
Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia. Leukemia research, 2020, Volume: 95 Topics: Adolescent; Antineoplastic Agents; Body Height; Child; Child, Preschool; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Retrospective Studies; Sex Characteristics	2020
JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). International journal of hematology, 2020, Volume: 112, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Consolidation Chemotherapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Philadelphia Chromosome; Practice Guidelines as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome; World Health Organization; Young Adult	2020
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood, 2021, 02-18, Volume: 137, Issue:7 Topics: Antibodies, Bispecific; Antineoplastic Agents; B-Lymphocytes; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Interferon-gamma Release Tests; Jurkat Cells; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mutation, Missense; Neoplasm Proteins; Phosphorylation; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-abl; Pyridazines; Pyrimidines; Receptors, Antigen, T-Cell; src-Family Kinases; T-Lymphocytes; Tumor Cells, Cultured	2021
CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells. Molecular medicine reports, 2020, Volume: 22, Issue:4 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Lentivirus; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Small Interfering; Signal Transduction; Tetraspanin 29	2020
Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion. Annals of hematology, 2021, Volume: 100, Issue:5 Topics: Adult; Bone Marrow; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators; Treatment Outcome; Young Adult	2021
[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9 Topics: Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2020
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. Leukemia, 2021, Volume: 35, Issue:7 Topics: Adolescent; Adult; Aged; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation, Homologous; Young Adult	2021
Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient. Pediatric hematology and oncology, 2021, Volume: 38, Issue:4 Topics: Adolescent; Antineoplastic Agents; Cerebral Hemorrhage; Humans; Imatinib Mesylate; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2021
Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 2022, Mar-01, Volume: 44, Issue:2 Topics: Bone Marrow; Child; Humans; Imatinib Mesylate; Male; Necrosis; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review. Medicine, 2021, Jun-11, Volume: 100, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Daunorubicin; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Male; Mutation; Pharmacogenomic Variants; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome; Vincristine; Young Adult	2021
Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Frontiers of medicine, 2017, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult	2017
Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leukemia research, 2017, Volume: 59 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; RNA, Messenger; Survival Rate	2017
Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. The Biochemical journal, 2017, 12-06, Volume: 474, Issue:24 Topics: Abietanes; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Female; Genes, p53; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome	2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukem Haematologica, 2018, Volume: 103, Issue:1 Topics: Biomarkers, Tumor; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulins; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Receptors, Antigen, T-Cell; Recurrence; Survival Analysis; Treatment Outcome	2018
10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation. International journal of hematology, 2018, Volume: 107, Issue:6 Topics: Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Stem Cell Transplantation; Time Factors; Treatment Outcome	2018
Remission is good - relapse is bad. Haematologica, 2018, Volume: 103, Issue:1 Topics: Chromosomes; Humans; Imatinib Mesylate; Immunoglobulins; Neoplasm, Residual; Philadelphia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Recurrence	2018
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult	2018
BCR-ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph Cancer medicine, 2018, Volume: 7, Issue:6 Topics: Adolescent; Adult; Apoptosis; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; Enzyme Activation; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; NIMA-Interacting Peptidylprolyl Isomerase; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Young Adult	2018
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Annals of hematology, 2018, Volume: 97, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult	2018
Down-regulation of CD19 expression inhibits proliferation, adhesion, migration and invasion and promotes apoptosis and the efficacy of chemotherapeutic agents and imatinib in SUP-B15 cells. Cell biology international, 2018, Volume: 42, Issue:9 Topics: Adaptor Proteins, Signal Transducing; Antigens, CD19; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction	2018
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. The Lancet. Haematology, 2018, Volume: 5, Issue:12 Topics: Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Survival Analysis; Treatment Outcome	2018
Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene. Acta haematologica, 2019, Volume: 141, Issue:2 Topics: Base Sequence; Child, Preschool; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Karyotype; Male; Microfilament Proteins; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Whole Genome Sequencing	2019
Demographics and Outcome of Philadelphia-positive ALL in a Pediatric Population in North India: a Single-center Experience. Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:5 Topics: Bone Marrow Examination; Central Nervous System Neoplasms; Child; Female; Humans; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukocyte Count; Male; Neutropenia; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Analysis; Treatment Outcome	2019
Huaier extract enhances the treatment efficacy of imatinib in Ik6 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Complex Mixtures; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Male; Mice, Inbred BALB C; Philadelphia Chromosome; Plant Extracts; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Trametes; Treatment Outcome	2019
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:1 Topics: Adolescent; Adult; Aged; Asian People; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Young Adult	2013
Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperati British journal of haematology, 2013, Volume: 162, Issue:3 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Drug Administration Schedule; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Analysis; Treatment Outcome	2013
Leukaemia. Nature, 2013, Jun-27, Volume: 498, Issue:7455 Topics: Benzamides; Child; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2013
[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia]. Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:3 Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult	2013
Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution. Pathology oncology research : POR, 2014, Volume: 20, Issue:1 Topics: Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
[Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:6 Topics: Antigens, CD; Benzamides; beta Catenin; Cadherins; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelium, Vascular; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA Interference	2013
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-01, Volume: 31, Issue:25 Topics: Benzamides; Child; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators	2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood, 2013, Aug-15, Volume: 122, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult	2013
Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib. Leukemia & lymphoma, 2014, Volume: 55, Issue:7 Topics: Antineoplastic Agents; Bone Marrow Transplantation; Child; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome	2014
Post-fracture excessive callus formation in a child on imatinib therapy. Pediatric blood & cancer, 2013, Volume: 60, Issue:12 Topics: Antineoplastic Agents; Benzamides; Bony Callus; Child, Preschool; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tibial Fractures	2013
Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. European journal of haematology, 2014, Volume: 92, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2014
Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL. British journal of haematology, 2014, Volume: 164, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunologic Memory; Immunophenotyping; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; T-Lymphocytes, Cytotoxic	2014
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood, 2014, Feb-06, Volume: 123, Issue:6 Topics: Adolescent; Adult; Aged; Benzamides; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Homologous; Young Adult	2014
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood, 2014, Mar-13, Volume: 123, Issue:11 Topics: Antineoplastic Agents; Benzamides; Child; Chromosome Aberrations; Cohort Studies; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Sequence Deletion; Survival Rate	2014
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr Cancer, 2014, Apr-01, Volume: 120, Issue:7 Topics: Adolescent; Adult; Aged; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Young Adult	2014
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia, 2014, Volume: 28, Issue:7 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chromosome Aberrations; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome; Young Adult	2014
Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2014, Volume: 55, Issue:11 Topics: Aged; Benzamides; Female; Humans; Imatinib Mesylate; Maintenance Chemotherapy; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Time Factors; Treatment Outcome	2014
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Genes, T-Cell Receptor; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2014
Ph+ ALL: imatinib grows older with patients. Blood, 2014, Feb-06, Volume: 123, Issue:6 Topics: Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2014
[Prognostic significance of Ph-positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Young Adult	2014
[Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
[Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
Pneumatosis intestinalis and imatinib mesylate. Annals of hematology, 2014, Volume: 93, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Child, Preschool; Dasatinib; Daunorubicin; Dexamethasone; Drug Substitution; Female; Humans; Imatinib Mesylate; Parenteral Nutrition, Total; Piperazines; Pneumatosis Cystoides Intestinalis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Vincristine	2014
[Outcome of autologous hematopoietic stem cell transplantation in combination with imatinib for 16 cases of Philadelphia chromosome positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3 Topics: Adolescent; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Autologous; Young Adult	2014
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget, 2014, Mar-15, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Heme Oxygenase-1; Humans; Imatinib Mesylate; Maleates; Metalloporphyrins; Nitrogen Mustard Compounds; Philadelphia Chromosome; Piperazines; Polyethylene Glycols; Polystyrenes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger	2014
Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. European journal of haematology, 2014, Volume: 93, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult	2014
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer, 2014, Dec-15, Volume: 120, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Karyotype; Karyotyping; Male; Middle Aged; Monosomy; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Pyrimidines; Remission Induction; Risk Adjustment; Young Adult	2014
Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN. Biochemical and biophysical research communications, 2014, 11-21, Volume: 454, Issue:3 Topics: Antagomirs; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotides; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; PTEN Phosphohydrolase; RNA Interference; RNA, Small Interfering; Up-Regulation	2014
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells. Leukemia research, 2015, Volume: 39, Issue:1 Topics: Amino Acid Substitution; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Benzodiazepinones; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Quinolines; Xenograft Model Antitumor Assays	2015
Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone marrow transplantation, 2015, Volume: 50, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Sequence Deletion; Treatment Outcome; Young Adult	2015
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22 Topics: Adolescent; Adult; Benzamides; Blast Crisis; Case-Control Studies; Chromosome Breakpoints; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult	2014
[Clinical study of 32 patients with adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Treatment Outcome	2014
Two cases of acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion transcript. Annals of laboratory medicine, 2015, Volume: 35, Issue:1 Topics: Antineoplastic Agents; Base Sequence; DNA; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Karyotyping; Male; Multiplex Polymerase Chain Reaction; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2015
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:2 Topics: Adult; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Infant, Newborn; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome	2016
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Adult; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors	2015
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica, 2015, Volume: 100, Issue:3 Topics: Adult; Antibodies, Bispecific; Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis	2015
Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Child; Female; Hepatitis; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Pyrimidines	2015
[Effects of stromal cells on sentitivity to imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:6 Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Stromal Cells	2015
The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell. Anti-cancer drugs, 2015, Volume: 26, Issue:9 Topics: Antineoplastic Agents; Autophagy; Benzamides; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Metformin; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured	2015
[Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2015, Volume: 17, Issue:8 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2015
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. PloS one, 2015, Volume: 10, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Ribavirin; Signal Transduction; TOR Serine-Threonine Kinases	2015
[Outcome of patients with adult acute lymphoblastic leukemia between 2000 and 2013: experience from single center]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:9 Topics: Acute Disease; Adult; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate	2015
[The impact of imatinib on hematopoietic stem cell transplantation for Ph chromosome positive adult acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:9 Topics: Adult; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2015
Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia. International journal of hematology, 2015, Volume: 102, Issue:6 Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dasatinib; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Young Adult	2015
Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells. Cancer letters, 2016, Feb-01, Volume: 371, Issue:1 Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Energy Metabolism; Fatty Acids; Fusion Proteins, bcr-abl; Glycolysis; Heterocyclic Compounds, 1-Ring; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Imatinib Mesylate; K562 Cells; Ketones; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplastic Stem Cells; Oxidation-Reduction; Polypyrimidine Tract-Binding Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyruvate Kinase; RNA Interference; Transfection	2016
[Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation, Homologous; Vindesine	2015
Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI. Leukemia research, 2016, Volume: 42 Topics: Antineoplastic Agents; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Niemann-Pick C1 Protein; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2016
Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation. Leukemia & lymphoma, 2016, Volume: 57, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Maintenance Chemotherapy; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome	2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget, 2016, Apr-19, Volume: 7, Issue:16 Topics: Adult; Aged; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Retrospective Studies	2016
[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Volume: 37, Issue:2 Topics: Chromosome Aberrations; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Retrospective Studies; Survival Rate	2016
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Journal of hematology & oncology, 2016, Apr-18, Volume: 9 Topics: Adolescent; Adult; Aged; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Young Adult	2016
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica, 2016, Volume: 101, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retreatment; Survival Analysis; Treatment Outcome; Young Adult	2016
Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. European journal of clinical pharmacology, 2016, Volume: 72, Issue:12 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2016
Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia. Medicine, 2016, Volume: 95, Issue:34 Topics: Adolescent; Adult; Anthracyclines; Antigens, CD19; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; CD79 Antigens; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Light Chains, Surrogate; Immunoglobulin M; Immunophenotyping; Induction Chemotherapy; Male; Middle Aged; Neprilysin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Sialic Acid Binding Ig-like Lectin 2; Vincristine; Young Adult	2016
Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. European journal of clinical pharmacology, 2016, Volume: 72, Issue:12 Topics: Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2016
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Molecular Targeted Therapy; Nuclear Pore Complex Proteins; Oncogene Protein v-akt; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases	2016
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. Oncotarget, 2016, Dec-06, Volume: 7, Issue:49 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Celecoxib; Cell Cycle Checkpoints; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Time Factors; Tumor Cells, Cultured	2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American journal of hematology, 2017, Volume: 92, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Disease-Free Survival; Female; Gene Deletion; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridazines; Survival Rate; Translocation, Genetic; Treatment Outcome; Young Adult	2017
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatric blood & cancer, 2017, Volume: 64, Issue:8 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Salvage Therapy	2017
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood, 2008, Aug-01, Volume: 112, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Risk Factors; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation	2008
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer, 2008, Sep-01, Volume: 113, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Molecular; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Salvage Therapy	2008
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood, 2008, Nov-01, Volume: 112, Issue:9 Topics: Adolescent; Adult; Aged; Alternative Splicing; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Genes, abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer genetics and cytogenetics, 2008, Volume: 185, Issue:1 Topics: Adult; Benzamides; Cell Line, Tumor; Cell Survival; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 6; Cytogenetic Analysis; Dose-Response Relationship, Drug; Genes, abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Sensitivity and Specificity; Translocation, Genetic	2008
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World journal of pediatrics : WJP, 2008, Volume: 4, Issue:2 Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood Cell Count; Central Nervous System Neoplasms; Chemoprevention; Child; Clinical Protocols; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Methotrexate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2008
Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. International journal of hematology, 2008, Volume: 88, Issue:3 Topics: Adult; Benzamides; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Living Donors; Lymphocyte Transfusion; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Siblings; Transplantation, Homologous	2008
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica, 2008, Volume: 93, Issue:11 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Colony-Forming Units Assay; Drug Resistance; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic	2008
Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone marrow transplantation, 2009, Volume: 43, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Regression Analysis; Retrospective Studies; Young Adult	2009
Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leukemia research, 2009, Volume: 33, Issue:3 Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Sirolimus; TOR Serine-Threonine Kinases	2009
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]. Bulletin du cancer, 2008, Volume: 95, Issue:9 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles	2008
Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Aged; Antifibrinolytic Agents; Antineoplastic Agents; Benzamides; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2009
Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT. Bone marrow transplantation, 2009, Volume: 43, Issue:7 Topics: Adolescent; Benzamides; Combined Modality Therapy; Dasatinib; Fatal Outcome; Genes, abl; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation Chimera	2009
Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:12 Topics: Adult; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Hyponatremia; Imatinib Mesylate; Inappropriate ADH Syndrome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2008
[Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib]. Zhonghua yi xue za zhi, 2008, Jul-22, Volume: 88, Issue:28 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult	2008
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles	2009
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leukemia research, 2009, Volume: 33, Issue:7 Topics: Adult; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl; Pyrimidines	2009
Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone marrow transplantation, 2009, Volume: 44, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tissue Donors; Transplantation Chimera	2009
Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. European journal of haematology, 2009, Volume: 83, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; DNA Primers; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Genes, abl; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Valproic Acid	2009
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Salvage Therapy; Vincristine; Vindesine; Young Adult	2009
[Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Treatment Outcome; Young Adult	2009
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer research, 2009, May-01, Volume: 69, Issue:9 Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides	2009
Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. Leukemia, 2009, Volume: 23, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Transplantation, Autologous	2009
Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Agents; Benzamides; Blood Coagulation Tests; Cross-Sectional Studies; Female; Follow-Up Studies; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thrombocytopenia; Treatment Outcome; Withholding Treatment	2009
Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen. British journal of haematology, 2009, Volume: 146, Issue:5 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Data Interpretation, Statistical; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Transplantation, Homologous	2009
JAK2 inhibitors: not the next imatinib but researchers see other possibilities. Journal of the National Cancer Institute, 2009, Jul-15, Volume: 101, Issue:14 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Point Mutation; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thrombocytosis	2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood, 2009, Sep-03, Volume: 114, Issue:10 Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles	2009
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta haematologica, 2009, Volume: 122, Issue:1 Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles	2009
The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. Pediatric blood & cancer, 2009, Volume: 53, Issue:6 Topics: Benzamides; Canada; Data Collection; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Physicians; Piperazines; Practice Patterns, Physicians'; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Siblings; Tissue Donors; Transplantation, Homologous; United States	2009
Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Infant; Male; Piperazines; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2009
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2009
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. Cytotherapy, 2010, Volume: 12, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome	2010
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Transplantation, Autologous	2010
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. European journal of haematology, 2010, Volume: 84, Issue:3 Topics: Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; Ephrin-B2; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Middle Aged; Neoplasm Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; ras Proteins; Receptor, EphB4; Recurrence; RNA, Small Interfering	2010
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology. American Society of Hematology. Education Program, 2009 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System; Child; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemic Infiltration; Mutation; Neoplasm Proteins; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Secondary Prevention; Thiazoles; Transplantation Conditioning	2009
Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Transplantation, Homologous; Treatment Outcome	2009
Possible alternative strategy for stage I imatinib-sensitive testicular seminoma; lessons from a case associated with Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Benzamides; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Seminoma; Testicular Neoplasms	2010
Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen? American journal of hematology, 2010, Volume: 85, Issue:3 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles	2010
[Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia]. Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:1 Topics: Adolescent; Adult; Benzamides; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2010
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia research, 2010, Volume: 34, Issue:8 Topics: Adult; Aged; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Diphtheria Toxin; Drug Synergism; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles	2010
Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. Leukemia & lymphoma, 2010, Volume: 51, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2010
Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2 Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left	2010
Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia, 2010, Volume: 24, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult	2010
[Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2010, Volume: 31, Issue:3 Topics: Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2010
Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer research, 2010, Volume: 30, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Transplantation, Homologous	2010
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 2010, Nov-04, Volume: 116, Issue:18 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles	2010
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia, 2011, Volume: 25, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cause of Death; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2011
[Current chemotherapy of adult acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2010
The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response. Leukemia, 2011, Volume: 25, Issue:2 Topics: Benzamides; Chromosome Breakpoints; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; RNA, Neoplasm; Transplantation, Homologous; Young Adult	2011
Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment. Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:4 Topics: Adult; Aged; Antigen Presentation; Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Separation; Cytokines; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Immunophenotyping; Killer Cells, Natural; Lymphocyte Activation; Male; Middle Aged; Phenotype; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; T-Lymphocytes; Young Adult	2011
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:5 Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines	2010
Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD. Bone marrow transplantation, 2012, Volume: 47, Issue:1 Topics: Adolescent; Benzamides; Bone Marrow Transplantation; Chronic Disease; Fasciitis; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous	2012
Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion. Leukemia & lymphoma, 2011, Volume: 52, Issue:7 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Treatment Outcome	2011
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leukemia & lymphoma, 2011, Volume: 52, Issue:7 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fatal Outcome; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Injections, Spinal; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Treatment Outcome	2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. International journal of hematology, 2011, Volume: 93, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles	2011
Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era? Leukemia & lymphoma, 2011, Volume: 52, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2011
Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy. Cancer biomarkers : section A of Disease markers, 2010, Volume: 7, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Benzamides; Biomarkers, Tumor; Dasatinib; Dose-Response Relationship, Drug; Enzyme Assays; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Thiazoles	2010
Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. Cancer science, 2011, Volume: 102, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Line, Tumor; Cyclohexanones; Disease Progression; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Luminescent Measurements; Mice; Neoplasm Proteins; NF-kappa B; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Fusion Proteins; Spleen; Stromal Cells; Transgenes; Transplantation, Heterologous; Tumor Burden; Tumor Microenvironment; Tumor Necrosis Factor-alpha	2011
Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Ear Diseases; Ear, External; Facial Dermatoses; Hematopoietic Stem Cell Transplantation; Humans; Hyperpigmentation; Imatinib Mesylate; Male; Maxillary Diseases; Neoplasms, Second Primary; Neurofibromatosis 1; Nose Diseases; Palate, Hard; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Tissue Conditioning, Dental	2012
Comparative quantitative analysis of BCR-ABL transcripts with the T315I mutant clone by polymerase chain reaction (PCR)-Invader method. Translational research : the journal of laboratory and clinical medicine, 2011, Volume: 158, Issue:3 Topics: Aged; Antineoplastic Agents; Base Sequence; Benzamides; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Oligonucleotide Probes; Piperazines; Point Mutation; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Neoplasm; Translational Research, Biomedical	2011
Validation of the 'French Acute Lymphoblastic Leukaemia Study Group FRALLE prognostic index' for paediatric Philadelphia-chromosome acute lymphoblastic leukaemia. British journal of haematology, 2012, Volume: 156, Issue:2 Topics: Benzamides; Child; Child, Preschool; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Reproducibility of Results; Retrospective Studies	2012
Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia, 2012, Volume: 26, Issue:4 Topics: Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Fusion Proteins, bcr-abl; G2 Phase; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survivin; Tumor Suppressor Protein p53	2012
Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Italy; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Retrospective Studies; Secondary Prevention; Transplantation, Homologous; Young Adult	2012
Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. International journal of hematology, 2011, Volume: 94, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2011
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia, 2012, Volume: 26, Issue:7 Topics: Adolescent; Adult; Aged; Benzamides; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult	2012
The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line. Leukemia research, 2012, Volume: 36, Issue:4 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, MDR; Humans; Imatinib Mesylate; Immunoblotting; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction	2012
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. British journal of haematology, 2012, Volume: 157, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Base Sequence; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Male; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Young Adult	2012
[Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:12 Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Retrospective Studies	2011
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. British journal of haematology, 2012, Volume: 158, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult	2012
Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 2012, Volume: 26, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Young Adult	2012
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer biology & therapy, 2012, Volume: 13, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Proliferation; Cell Survival; Diterpenes, Kaurane; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; raf Kinases; RNA, Messenger; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2012
Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia. The Lancet. Oncology, 2012, Volume: 13, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2012
MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia. Cancer genetics, 2012, Volume: 205, Issue:9 Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Child; Clonal Evolution; Cohort Studies; DNA Copy Number Variations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Nucleic Acid Amplification Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence	2012
[Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2012, Volume: 43, Issue:5 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger	2012
Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia? European journal of haematology, 2013, Volume: 90, Issue:4 Topics: Adult; Animals; Anthocyanins; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Caspases; Cell Line, Tumor; Cell Proliferation; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Maintenance Chemotherapy; Mice; Mice, Transgenic; Piperazines; Plant Extracts; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vaccines, DNA	2013
As leukemia options grow, drugs jockey to be first-line therapies. Nature medicine, 2013, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles	2013
The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome	2013
Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia. Leukemia, 2002, Volume: 16, Issue:10 Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Proteins; Recurrence; Remission Induction	2002
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. British journal of haematology, 2002, Volume: 119, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Central Nervous System Neoplasms; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2002
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. Bone marrow transplantation, 2002, Volume: 30, Issue:12 Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine	2002
Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia. Haematologica, 2002, Volume: 87, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Transplantation Conditioning	2002
TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood, 2003, May-01, Volume: 101, Issue:9 Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Arabidopsis Proteins; Benzamides; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 1; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fas Ligand Protein; Fatty Acid Desaturases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leupeptins; Membrane Glycoproteins; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Peptides; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2003
Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood, 2003, Mar-15, Volume: 101, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Skin Diseases	2003
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Bone Marrow; Clinical Trials, Phase II as Topic; Clone Cells; Cohort Studies; DNA Mutational Analysis; DNA, Complementary; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation, Missense; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Point Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Selection, Genetic; Time Factors	2003
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias. Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hepatitis B; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lamivudine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Salvage Therapy; Vincristine	2003
[Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2003
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene, 2003, Oct-09, Volume: 22, Issue:44 Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Benzamides; Enzyme Inhibitors; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Monocytes; Oxides; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transgenes; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells; Up-Regulation	2003
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer research, 2003, Oct-01, Volume: 63, Issue:19 Topics: Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Transformed; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines	2003
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia, 2004, Volume: 18, Issue:1 Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured	2004
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:4 Topics: Administration, Oral; Aged; Benzamides; Biological Availability; Chromatography, High Pressure Liquid; Half-Life; HL-60 Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Clearance Rate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2004
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. British journal of haematology, 2004, Volume: 124, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Karyotyping; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Translocation, Genetic	2004
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. European journal of haematology, 2004, Volume: 72, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Doxorubicin; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Neoplasm Proteins; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Vincristine	2004
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leukemia & lymphoma, 2004, Volume: 45, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction	2004
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood, 2004, Sep-01, Volume: 104, Issue:5 Topics: Antigens, CD19; Antigens, CD34; Antineoplastic Agents; Benzamides; Burkitt Lymphoma; Cell Death; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Liposomes; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured	2004
Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. International journal of hematology, 2004, Volume: 80, Issue:1 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Rituximab; RNA, Messenger	2004
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica, 2004, Volume: 89, Issue:10 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Drug Evaluation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Life Tables; Neoplasm Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis	2004
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:12 Topics: Adolescent; Adult; Aged; Benzamides; Graft Rejection; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stem Cell Transplantation; Time Factors; Treatment Outcome	2004
Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. Journal of immunology (Baltimore, Md. : 1950), 2005, Jan-01, Volume: 174, Issue:1 Topics: B-Lymphocytes; Benzamides; DNA Primers; DNA-Binding Proteins; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Gene Rearrangement, B-Lymphocyte, Light Chain; Guanine Nucleotide Exchange Factors; Homeodomain Proteins; Humans; Imatinib Mesylate; Immunoglobulins; Nuclear Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells; Transcription Factors	2005
In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Benzamides; Cell Survival; Child; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Male; Mutation, Missense; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2005
Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2005
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatric research, 2005, Volume: 57, Issue:3 Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Survival; Child; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genes, abl; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Rifabutin	2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer cell, 2005, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Line; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Models, Chemical; Mutation; Mycoplasma; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retroviridae; Time Factors	2005
Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood, 2005, Jun-15, Volume: 105, Issue:12 Topics: Adolescent; Base Sequence; Benzamides; Blotting, Western; Cell Line; Cell Survival; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 9; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; DNA, Complementary; Female; Fusion Proteins, bcr-abl; Gene Deletion; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Microtubules; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Genetic; Molecular Sequence Data; Oncogene Proteins, Fusion; Open Reading Frames; Phenotype; Phosphorylation; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT5 Transcription Factor; Time Factors; Trans-Activators; Translocation, Genetic	2005
Cytogenetic abnormalities without evidence of relapse after treatment with imatinib and stem cell transplantation in a patient with Ph-positive ALL. International journal of hematology, 2005, Volume: 81, Issue:2 Topics: Benzamides; Chromosome Aberrations; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Transplantation Chimera	2005
Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. American journal of ophthalmology, 2005, Volume: 139, Issue:4 Topics: Anterior Chamber; Antineoplastic Agents; Aqueous Humor; Benzamides; Eye Neoplasms; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Uveitis, Anterior	2005
Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients. Leukemia research, 2005, Volume: 29, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis	2005
In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia. Anti-cancer drugs, 2005, Volume: 16, Issue:6 Topics: Adult; Antineoplastic Agents; Asparaginase; Benzamides; Cell Survival; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Fluorometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mercaptopurine; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Pyrimidines; Tumor Cells, Cultured; Vincristine	2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer, 2005, Sep-15, Volume: 104, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2005
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. British journal of haematology, 2005, Volume: 130, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diphosphonates; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured; Zoledronic Acid	2005
[Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. Terapevticheskii arkhiv, 2005, Volume: 77, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2005
Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. Haematologica, 2005, Volume: 90, Issue:9 Topics: Adult; Aged; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2005
Adult ALL: where are we and where are we going? Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:6 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Middle Aged; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis	2004
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. The Lancet. Oncology, 2005, Volume: 6, Issue:10 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2005
Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Brain Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2005 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Stem Cell Transplantation; Survival Rate	2005
BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays? Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 2005, Volume: 9, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity	2005
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia, 2006, Volume: 20, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vincristine	2006
Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology, 2006, Volume: 105, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Hyperplasia; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vasodilator Agents	2006
Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of hematology, 2006, Volume: 85, Issue:8 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Humans; Imatinib Mesylate; Male; Necrosis; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:5 Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Middle Aged; Philadelphia Chromosome; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiography	2006
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood, 2006, Aug-15, Volume: 108, Issue:4 Topics: Adult; Benzamides; Blast Crisis; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Graft Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2006
Circumventing resistance to kinase-inhibitor therapy. The New England journal of medicine, 2006, Jun-15, Volume: 354, Issue:24 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2006
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. The Annals of thoracic surgery, 2006, Volume: 82, Issue:1 Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Bone Marrow Transplantation; Cefepime; Cephalosporins; Combined Modality Therapy; Cunninghamella; Daunorubicin; Drug Resistance, Multiple, Fungal; Female; Humans; Imatinib Mesylate; Immunocompromised Host; Lung Diseases, Fungal; Middle Aged; Neutropenia; Piperazines; Pneumonectomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Transplantation Conditioning; Triazoles; Vancomycin; Vincristine; Voriconazole; Zygomycosis	2006
[Ph+ acute lymphoblastic leukemia combined with lung and brain invasive aspergillosis]. Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:3 Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Benzamides; Brain Diseases; Humans; Imatinib Mesylate; Itraconazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Fungal; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia, 2006, Volume: 20, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Methylprednisolone; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2006
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta bio-medica : Atenei Parmensis, 2006, Volume: 77 Suppl 2 Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole	2006
Activity of AMN107 in gleevec-resistant leukemia. Cancer biology & therapy, 2006, Volume: 5, Issue:1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplant International journal of hematology, 2006, Volume: 84, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Humans; Imatinib Mesylate; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous	2006
Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status. American journal of hematology, 2007, Volume: 82, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Blotting, Western; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Imatinib Mesylate; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Risk Factors; Tissue Donors; Treatment Outcome	2007
Dasatinib (Sprycel) for CML and Ph + ALL. The Medical letter on drugs and therapeutics, 2007, Jan-15, Volume: 49, Issue:1252 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2007
Leukaemic infiltration of the mandible in a young girl. International journal of paediatric dentistry, 2007, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Dexamethasone; Female; Humans; Imatinib Mesylate; Leukemic Infiltration; Mandible; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2007
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 2007, Jul-15, Volume: 110, Issue:2 Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Bone Marrow Cells; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Survival Analysis	2007
What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL? Leukemia research, 2007, Volume: 31, Issue:10 Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiotherapy; Salvage Therapy	2007
Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. International journal of hematology, 2007, Volume: 85, Issue:3 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dexamethasone; Female; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Vincristine	2007
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica, 2007, Volume: 92, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Gene Deletion; Gene Rearrangement, B-Lymphocyte; Gene Rearrangement, T-Lymphocyte; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Kinetics; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrimidines; Remission Induction; Risk; Survival Analysis; Survival Rate; T-Cell Acute Lymphocytic Leukemia Protein 1; Translocation, Genetic; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2007
Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. International journal of oncology, 2007, Volume: 31, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Cluster Analysis; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk	2007
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes & development, 2007, Sep-15, Volume: 21, Issue:18 Topics: Animals; Antineoplastic Agents; Benzamides; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Imatinib Mesylate; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, SCID; Models, Biological; Neoplasm Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Treatment Failure	2007
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:6 Topics: Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Translocation, Genetic	2007
Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL. Genes & development, 2007, Sep-15, Volume: 21, Issue:18 Topics: Animals; Antineoplastic Agents; Benzamides; Burkitt Lymphoma; Disease Progression; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice; Models, Biological; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2007
Where lies the blame for resistance--tumor or host? Nature medicine, 2007, Volume: 13, Issue:10 Topics: ADP-Ribosylation Factor 1; Animals; Benzamides; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Ligands; Mice; Models, Immunological; Neoplasms, Experimental; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Receptors, Cytokine	2007
Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation. Leukemia & lymphoma, 2007, Volume: 48, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chimerism; Cord Blood Stem Cell Transplantation; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Thiazoles; Time Factors	2007
Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leukemia research, 2008, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Phosphatidylinositol 3-Kinases; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines	2008
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome	2007
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous	2007
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous	2007
Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2007, Volume: 92, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Flow Cytometry; Humans; Imatinib Mesylate; Male; Neoplasm Staging; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous	2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leukemia research, 2008, Volume: 32, Issue:6 Topics: Antineoplastic Agents; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoassay; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity	2008
Successful treatment with interferon-alpha-2b and imatinib in an adult Japanese male with Philadelphia chromosome-positive acute lymphoblastic leukemia and minimal residual disease following allogeneic transplantation. Bone marrow transplantation, 2008, Volume: 41, Issue:9 Topics: Antineoplastic Agents; Asian People; Benzamides; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Homologous	2008
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-15, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration	2008
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Imatinib Mesylate; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Program Development; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Time Factors	2008
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leukemia research, 2008, Volume: 32, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine	2008
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica, 2008, Volume: 93, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuclear Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2008
Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib. Pediatric blood & cancer, 2008, Volume: 51, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Central Nervous System Neoplasms; Child; Cranial Irradiation; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2008
Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. Journal of clinical pharmacy and therapeutics, 2008, Volume: 33, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Insufficiency; Thiazoles	2008
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia research, 2009, Volume: 33, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Stem Cell Transplantation	2009
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:7 Topics: Apoptosis; Benzamides; Cell Division; Cell Survival; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; Tumor Cells, Cultured	1998
Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia, 2001, Volume: 15, Issue:4 Topics: Adolescent; Adult; Aged; Animals; Benzamides; Cell Division; Female; Genes, abl; Humans; Imatinib Mesylate; Male; Mice; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl; Pyrimidines	2001
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia, 2001, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Oncogene Proteins v-abl; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Pyrimidines; Substrate Specificity; Tumor Cells, Cultured	2001
Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica, 2001, Volume: 86, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Lymphocyte Transfusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Transplantation, Homologous; Treatment Outcome	2001
Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 2001, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2001
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer research, 2001, Nov-01, Volume: 61, Issue:21 Topics: Benzamides; Blast Crisis; Cyclin D2; Cyclins; Down-Regulation; Fusion Proteins, bcr-abl; G1 Phase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Phosphatidylinositol 3-Kinases; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; S Phase; Signal Transduction; Transfection	2001
Research on resistance to cancer drug Gleevec. Science (New York, N.Y.), 2001, Nov-30, Volume: 294, Issue:5548 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinases; Protein Structure, Tertiary; Pyrimidines; Reproducibility of Results	2001
Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Lysis Syndrome	2002
[Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec)]. Medizinische Klinik (Munich, Germany : 1983), 2002, Jan-15, Volume: 97 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines	2002
Resistance to targeted therapy in leukaemia. Lancet (London, England), 2002, Feb-09, Volume: 359, Issue:9305 Topics: Benzamides; Drug Resistance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2002
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet (London, England), 2002, Feb-09, Volume: 359, Issue:9305 Topics: Adult; Aged; Benzamides; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2002
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 2002, Mar-01, Volume: 99, Issue:5 Topics: Antineoplastic Agents; Base Sequence; Benzamides; Bone Marrow Cells; DNA, Complementary; Drug Resistance; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 2002, May-01, Volume: 99, Issue:9 Topics: Adenosine Triphosphate; Adult; Aged; Benzamides; Binding Sites; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2002
Imatinib mesylate (Gleevec) in the treatment of 2 patients with Philadelphia-positive ALL relapsing after allogeneic stem cell transplantation. International journal of hematology, 2002, Volume: 75, Issue:4 Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2002